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There is a theory which states that if ever anyone discovers exactly what the universe is for 
and why it is here, it will instantly disappear and be replaced by something even more bizarre 
and inexplicable. 
 
 
 
 
There is another theory which states that this has already happened. 
 
 
 
 
 
Don’t panic! 
 
 
 
 
Douglas Adams - The Restaurant at the End of the Universe 
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Summary 
Sjögren’s syndrome (SS) is a systemic rheumatic disease, in which the salivary and lacrimal 
glands are the principal targets of a pathological autoimmune reaction. Clinically, SS is 
manifested by keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth). 
Histopathologically, the disease is characterized by persistent focal mononuclear cell 
infiltration in the salivary glands. Traditionally, loss of secretory capacity, degree of lymphoid 
infiltration and production of specific autoantibodies were anticipated to correlate with each 
other and indicate disease state and disease severity. The correctness of this assumption was, 
however, difficult to prove. 
The aim of the first study was to clarify the chronology of the SS disease course and to 
describe possible interrelationships between sialoadenitis and hyposalivation. We could 
confirm that the SS in non-obese diabetic (NOD) mice is characterized by at least two distinct 
phases. In our study, inflammation of the salivary glands preceded the onset of hyposalivation 
with a considerable amount of time. Interestingly, the onset of hyposalivation was not 
associated with a significantly higher degree of inflammation. Significant alterations in 
cytokines in serum and saliva paralleled the transition from the pre-clinical to the overt 
disease state. 
The purpose of the second study was to acquire knowledge on 87 immunologically relevant 
proteins measured in serum and 75 proteins analyzed in saliva. Thirty-eight biomarkers 
analyzed in serum and 34 proteins in saliva from NOD mice were significantly altered when 
compared to Balb/c mice. Eighteen biomarkers in serum and 3 chemokines in saliva had the 
potential to predict individual strain-membership with 80-100% accuracy. Computation of a 
correlation network led to the conclusion that processes related to the adaptive immune 
system promote SS with a strong implication of T-helper (TH)2 related proteins in 
hyposalivation. In addition, the SS-related disease manifestations appeared to be associated 
with different immunological processes and did not correlate with each other. Cluster of 
differentiation (CD)40, CD40L, interleukin-18, granulocyte chemotactic protein-2 (GCP-2) 
and anti-muscarinic M3 receptor immunoglobulin G3, may, however, interrelate the different 
aspects of SS. The study further established saliva as an attractive biofluid for biomarker 
discovery in SS and provides a basis for the comparison and selection of potential drug targets 
and diagnostic markers. 
The third study was conducted to investigate a potential immunomodulatory effect of heat-
shock protein 60kDa (Hsp60) and Hsp60-derived peptide aa437-460 (aa437-460) 
immunization on spontaneous experimental SS. Administration of Hsp60 and aa437-460 
significantly reduced SS-related histopathology compared to the untreated NOD controls. In 
addition, 50% of Hsp60 and 33% of aa437-460 injected mice retained normal exocrine 
function. Both treatments induced similar changes in the biomarker profiles, which indicated 
decreased inflammatory chemotaxis and strengthened anti-inflammatory regulatory pathways. 
Successful prevention of hyposalivation was accompanied by quantitative alterations in 36 
biomarkers, of which 19 inflammatory mediators declined to levels comparable to the 
measurements obtained in Balb/c mice. Molecules involved in inflammatory chemotaxis, 
neovascularization and regulatory pathways coined the differences displayed by the biomarker 
profiles. In addition, specific biomarker signatures had the capability to accurately predict the 
received treatment, treatment efficacy and impaired exocrine function.  
Common to all three studies were the appearing independence of the different aspects of SS 
and the valuable information we could extract from biomarker analyses especially in saliva. 
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Background 
On science 
In the broadest sense, science refers to any systematic knowledge or practice. Applying a 
more restrictive definition, science refers to a system of acquiring knowledge applying the 
scientific method. The scientific method is based on the collection of data through observation 
and experimentation, and the formulation and testing of hypotheses. The organized body of 
knowledge gained through such research is as well referred to as science. Scientists shall 
never claim absolute knowledge of nature or the behavior of the subject of study, as a 
scientific theory is empirical and always open to falsification.  
 
I am being scientific; illustration by Sam Brown (www.explodingdog.com) 
The two major principles applied in science are the principle of reductionism and the principle 
of holism. Until today the scientific method has primarily tended towards reductionism what 
led to enormous scientific advances since the age of enlightenment. In many ways 
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reductionism also liberates us from the annoyance of complexity. Descartes argued in 1637 
that the world is like a machine, its pieces like clockwork mechanisms. The machine could be 
understood by taking its pieces apart, studying them, and by putting them back together one 
would grasp the larger context [1]. Reductionism in science is based on the philosophical 
position that a complex system is nothing but the sum of its parts. Metaphorically, one 
reduces complexity to causal principles. Complex systems can therefore be accounted for with 
a hierarchy of organizations, of which each higher level can be described by the levels lower 
in the hierarchy [2]. While it is widely accepted that mathematics underlie most aspects of 
physics and physics provide the basis for chemistry and so forth, at levels of organization with 
higher amounts of complexity, formed from assemblies of large numbers of interacting 
components, such statements may become controversial [3].  
Aristotle concisely summarized holism by stating, “The whole is more than the sum of its 
parts” what implies that complex systems are inherently irreducible and a holistic approach is 
needed to understand them. Promoted by the revolution in information technology and the 
recent developments of powerful bioanalytical platforms, system-based approaches have 
emerged within the field of bioscience [4, 5]. System biology promotes integration rather than 
reduction, driven by the ultimate goal to display a complete and accurate model of a 
biological system at a given time. Intuitively and intellectually, one may conclude that both, 
hypothesis-driven component focused research, and discovery-oriented systematic approaches 
are needed to properly account for a specific system state. The challenges in the years to come 
will also consist of finding ways to bridge between these two principles of research [4, 5]. 
On immunity 
“The story of immunity is the story of the self. The immune system, like the brain, creates, 
records and protects our individuality” Irun R. Cohen [6]. 
The immune system greatly defines us as a species and an individual of this species by 
defining what is allowed to reside within us. It protects our body against pathogens, rejects 
foreign tissue and eliminates tumor cells [7]. In addition, the immune system is involved in 
body maintenance and paves the path for reconstruction, which follows non-lethal injury [7].  
Immunology is a relatively new science, having its origins in Edward Jenner’s discovery 
made in 1796. He described that cowpox had the capacity to induce protection against human 
smallpox [8]. The causal relationship between a specific pathogen and a specific infectious 
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disease, however, was only defined at the end of the 19th century. The triumph of vaccination 
in fighting infectious diseases led to emergence of the research discipline termed immunology 
[7].  
 
You are not immune; Illustration by Sam Brown (www.explodingdog.com) 
Immunology covers the study of all aspects of the immune system in all organisms and in 
states of health and disease. Malfunctions of the immune system include hypersensitivities, 
immune deficiency, allograft rejection and autoimmune diseases [7]. The latter are addressed 
in further detail in the following chapters. 
It should be recognized, that every organism has an immune system capable of protecting it 
from specific forms of harm. Nevertheless, the different species maintain immune systems of 
different complexity, often involving layered defense mechanisms with varying specificities. 
Most simply, surface barriers such as physical barriers e.g. skin, chemical barriers e.g. 
alterations in the pH and biological barriers e.g. commensal flora competing with potential 
pathogens for resources, prevent pathogens from invading the body [7].  
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Innate immunity 
The next layer of defense, termed the innate immune system, exists in nearly all forms of life 
and elicits an immediate immune response in case surface barriers have been breached. The 
symptoms of inflammation that are redness, heat, swelling, pain and loss of function indicate 
the activation of the innate immune system. These clinical manifestations reflect vasodilation 
of local blood vessels in favor of the recruitment of immune cells to sites of injury. In 
addition, the complement cascade is activated, representing the mobilization of the humoral 
component of the innate immune response. Elevation of the body temperature is mainly 
caused by endogenous pyrogens such as tumor necrosis factor (TNF)-α, interleukin (IL)-1 and 
IL-6, which in their turn initiate the acute-phase response approximately 90 minutes after the 
onset of a systemic inflammatory reaction [7]. In many cases, the invading pathogens can be 
recognized and eliminated through preformed nonspecific effectors. Subsequently, processes 
mediating tissue repair replace the inflammatory reaction. 
In other cases, although the innate immune system lacks fine specificity, certain cells such as 
macrophages, neutrophils and dendritic cells (DCs) recognize common microbe-associated 
molecular patterns through receptors located on their cell membranes or in their intracellular 
compartments [7]. In mammals, Toll-like receptor (TLR)4 binds lipopolysaccharide (LPS), an 
important component of the outer membrane of Gram-negative bacteria [9]. TLR engagement 
triggers the production of chemokines and cytokines and the expression of co-stimulatory 
molecules. The expression of the latter is crucial to initiate an adaptive immune response 
through a process referred to as antigen presentation [7]. In addition to the cell types already 
mentioned, mast cells, eosinophils and basophils belong to the cell types categorized as innate 
leukocytes [7]. At the interface of the innate and adaptive immune system, minor subsets of 
innate-like lymphocytes (B-1 cells, γ:δ T-cells and natural killer [NK] T-cells) have been 
described [7]. They only express a limited diversity of receptors and are mainly confined to 
specific locations in the body. Furthermore, they are not required to undergo clonal expansion 
before responding efficiently to the antigens they recognize. However, their exact role in host 
defense and immunological disorders is still a matter of speculation. Common to all processes 
belonging to the innate immune system is the lack of adaptation subsequently to a pathogen 
encounter and their incapability of generating a noteworthy immunological memory [7].  
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Adaptive immunity 
The adaptive immune system is thought to have arisen in the first jawed vertebrates. It is 
composed of highly specialized cells and processes, which become activated when pathogens 
evade the innate immune system. Compared to the innate immune response, the adaptive 
immune system provides the individual with the ability to selectively recognize and remember 
specific pathogens and to mount a more potent immune response each time the pathogen is 
reencountered (immunological memory) [7]. T-cells and B-cells are the two cell types 
involved in specific antigen recognition and capable of generating immunological memory. 
Both subsets use different, but structurally similar molecules, which specifically bind a certain 
antigen. The antigen-recognition molecules of T-cells are membrane bound and referred to as 
T-cell receptors (TCRs). Antigen-recognition molecules on B-cells are membrane bound 
immunoglobulins (Ig’s) and are referred to as B-cell receptors (BCRs) [7]. Ig’s can also be 
secreted by highly differentiated B-cell subsets (plasma cells, plasma blasts). Secreted Ig’s, 
also known as antibodies, form the humoral component of the adaptive immune response. The 
large repertoire of the TCRs and the BCRs is based on the mechanism of V(D)J 
recombination (an irreversible genetic recombination of antigen receptor gene segments). 
BCRs are furthermore modified by mutations, known as somatic hypermutations, of the 
variable regions within the Ig. These two mechanisms allow a small number of genes to 
generate a vast number of different antigen receptors, which has theoretically been estimated 
at 1018 for T-cells and 5x1013 for B-cells [7]. Because the gene rearrangements lead to 
irreversible changes in the DNA, all of the progeny of one specific T- or B-cell will inherit 
genes encoding the same receptor specificities.  
The activation of T-cells is dependent upon recognition of considered “non-self” protein 
fragments (peptides) presented within a protein structure, termed the major histocompatibility 
complex (MHC) [10]. MHC class I molecules present peptides derived from proteins 
synthesized in the cytosol (e.g. viruses). MHC class II molecules stably bind peptides from 
proteins degraded in the endocytic vesicles (e.g. phagocytized bacteria). MHC class I and 
MHC class II are differentially recognized by the co-receptor molecules cluster of 
differentiation (CD)8 and CD4, respectively [7]. At the same time the expression of CD4 and 
CD8 categorizes T-cells into two major subsets, the CD8+ and CD4+ T-cells. CD8+ T-cells are 
mainly cytotoxic T-cells specialized to release preformed cytotoxins e.g. perforin and 
granzymes. Tightly focused at the site of contact between the two cells, cytotoxins either 
perforate the membrane or induce apoptosis of the target cells [7]. Whereas MHC class 
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I/peptide complexes can be expressed on nearly all cells, MHC class II molecules are almost 
exclusively expressed on professional antigen presenting cells. CD4+ T-cells recognize the 
MHC class II/peptide complexes on antigen presenting cells and are specialized to activate 
other immune effector cells, e.g. B-cells and macrophages, to act against the antigen they are 
presenting [7].  
B-cells, through their BCR, have the unique capability of recognizing their cognate antigen in 
its native form. Alike other professional antigen presenting cells, B-cells present protein 
antigens in form of peptide/MHC class II complexes to CD4+ T-cells. Upon ligation, T-cells 
secrete cytokines, providing B-cells with so-called T-cell help. These cytokines trigger B-cell 
proliferation, isotype switching to IgG, IgA, and IgE, and promote differentiation towards 
plasma cells and memory B-cells. Many B-cells are dependent on the co-stimulatory signals 
provided by T-cells. However, other antigens, such as repeating carbohydrate epitopes, are 
considered to be T-cell independent, meaning they deliver all necessary signals to the B-cells 
to become activated. B-cells recognizing T-cell independent antigens require extensive BCR 
cross-linking to mount an immune response, which is characterized by only few or no somatic 
mutations, limitations in Ig class switching and weak memory. Indeed, T-cell independent 
immune reactions comprise many characteristics initially associated with the innate immune 
system [7]. 
The goal of every immune response must be the survival of an infection by either eliminating 
or confining the specific pathogen in a manner so it cannot inflict harm on the host any 
longer. At the same time, damages on the surrounding tissue have to be limited. The immune 
system also needs to ensure the restoration of tissue homeostasis, whenever possible, without 
causing secondary effects such as fibrosis. These multiple tasks require the generation of fine-
tuned and controlled immune responses.  
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Mediators of the immune system 
Cytokines 
The term cytokine is used for a diverse group of soluble proteins and peptides that act as 
humoral regulators at nano- to picomolar concentrations [7]. Under normal and pathological 
conditions they modulate the functional activities of individual cells and tissues. Their 
mechanisms of action may be classified as autocrine (acts on the cytokine secreting cell 
itself), juxtacrine (involving specific cell-to-cell contacts), paracrine (effect is restricted to the 
immediate vicinity of the cytokine secreting cell) and endocrine (diffuses to distant regions of 
the body) [7]. Because cytokines are characterized by redundancy, pleiotropism, synergism, 
and antagonism and can be secreted by a wide range of cell-types, the initial concept of "one 
producer cell - one cytokine - one target cell" has been falsified for practically every cytokine 
investigated. Generalizing the functions of cytokines is also impossible because beside their 
central role in immune system, not all their functions are restricted to immune reactions. They 
are, furthermore, involved in several developmental processes such as embryogenesis and 
hematopoiesis [7].  
Nonetheless, classification according to structural homology has been able to subdivide 
cytokines in several, sometimes rather large families: 1) the hematopoietins, e.g. many ILs 
and growth factors such as the granulocyte macrophage-colony stimulating factor (GM-CSF), 
2) the interferons (IFNs) and 3) the TNF superfamily e.g. TNF-α, CD40L, FasL and B-cell 
activating factor (BAFF) [11], 4) the more recently discovered IL-17 family e.g. IL-17 [12] 
and 5) the chemokines [13]. Accordingly, their specific receptors can be grouped similarly: 1) 
The class I cytokine receptors recognizing the hematopoietins, 2) the class II cytokine 
receptors binding IFN-α, -β, -γ and IL-10 superfamily and so forth [7]. However, cytokines, 
which are sharing structural similarities, may, but often do not, exert similar biological 
functions. Nevertheless, hematopoietins and IFNs, all signal through similar pathways, 
involving members of the Janus family of cytoplasmatic tyrosine kinases (JAK) and signal 
transduction and activators of transcription (STAT). Because the JAK and STAT protein 
families are comprised of different members, they can be individually activated to achieve 
very specific effects [7]. 
Based on the cytokines secreted, T-helper (TH) cells are currently subdivided into three 
distinct functional effector subsets, termed TH1, TH2 and TH17 [12, 14, 15] (Figure 1). They 
differentiate from not yet committed TH0 cells in response to exposure to specific cytokines. 
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Such stimuli are followed by the induction of independent patterns of gene transcription. TH1 
cells tend to be involved in host defense against intracellular pathogens and thought to 
perpetuate autoimmune responses [12, 14]. TH1 cell differentiation from TH0 cells is 
dependent on IFN-γ and IL-12. In their turn, TH1 cells produce IL-2 and IFN-γ. TH2 cells on 
the other hand tend to engage in immune responses, which depend on a substantial humoral 
component to eliminate the pathogen [12, 14]. Key molecules of a TH2 dominated immune 
response are IL-4, IL-5 and IL-13. TH1 and TH2 cells counteract each other, mainly because 
their respective cytokines can exert an inhibitory effect on the opposite TH cell subset [12, 
14].  
Hence, an optimal scenario, before the emergence of TH17 and regulatory T-cells (Treg) cell 
subsets, seemed to consist of a well balanced TH1 and TH2 response, tailored in accordance 
with the encountered immune challenge [14]. Indeed, considering the limited knowledge 
about cytokines at the time the TH1/TH2 model was developed [14] and despite its flaws, the 
TH1/TH2 paradigm showed remarkable durability and still conserved some of its validity [16].  
  
Figure 1) T-helper cell differentiation and regulation. Green arrows and black indicate 
induction, while red lines indicate inhibition. Transcription factors for particular lineages are 
placed in the nucleus. Differentiation of CD4+ T-cell lineages: Peripheral naive CD4+ T-cell 
precursor cells (THp) can differentiate into three subsets of effector T-cells (TH1, TH2 and 
TH17) and several subsets of Tregs, including induced Treg cells (iTreg), Tr1 cells and TH3 cells. 
Naturally occurring Treg cells (nTreg) are generated from CD4+ thymic T-cell precursors. The 
differentiation of these subsets is governed by selective cytokines and transcription factors, 
and each subset accomplishes specialized functions. Figures fully borrowed from L. Steinman 
[12] and E. Betelli et al. [17]. 
More recently the TH1/TH2 paradigm has been challenged by the emergence of the TH17 
subset producing IL-17 (IL-17A), IL-17F and IL-22 [12, 15]. A major role of IL-17 has now 
been described in various models of immune mediated tissue injury related with host defense 
against microorganisms and organ-specific autoimmunity [15, 17]. IL-6, transforming growth 
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factor (TGF)-β and IL-23 induce the differentiation, survival and expansion of TH17 cells, 
whereas the major cytokines produced in a TH1 and TH2 context, IFN-γ and IL-4, 
respectively, antagonize TH17 related immune responses [18]. Furthermore, reciprocal 
interactions involving TH17 cells have been reported when studying the differentiation of a 
class of Tregs termed forkhead box P3 (Foxp3)+ Tregs. This process involves IL-6 and TGF-β 
(Figure 1). TGF-β, initially thought of as anti-inflammatory, was proposed to function as a 
critical regulator of both tissue-damaging TH17 cells when collaborating with IL-6, and as an 
inducer of anti-inflammatory Tregs when acting in absence of IL-6 [17] (Figure 1). The 
mechanism by which Tregs limit effector responses in vivo, however, remains poorly 
understood. Crucial however, seems the secretion of anti-inflammatory cytokines, such as 
TGF-β and IL-10 by Tregs [19, 20]. In addition, Tregs may reduce the ability of DCs to 
subsequently activate effector T-cells [21].  
It is certain, that the current concept of how cytokines and T-cell subsets achieve an 
appropriate balance between protection from “non-self”, while sparing the “self” from self 
inflicted damage, will continue to increase in terms of size and complexity. Even though T-
cell populations have received most attention over the recent years, it is important to 
remember that virtually all populations of cells, especially in close proximity of the 
inflammation, may contribute in one or another way to the outcome of the immune reaction.  
Chemokines 
Chemokines are a family of 8-10kDa small, secreted proteins, mainly involved in leukocyte 
chemoattraction during the initiation and orientation of the innate and adaptive immune 
response. Beside their role in inflammation, chemokines are of importance in regulating cell 
trafficking in states of tissue development and tissue homeostasis [7, 13]. This large family of 
related molecules is classified according to structural properties related to the number and 
position of conserved cysteine residues. C-C motif (CC) and C-X-C motif (CXC) chemokines 
are the two major, and C motif (XC) and C-X3-C motif (CX3C) the two minor chemokine 
subfamilies [22] (Figure 2). Accordingly, the different subfamilies bind to specific receptors, 
all belonging to the G-protein-coupled receptor superfamily. Most chemokines can bind to 
several receptors [13], named according to the subfamily of chemokines they recognize e.g. 
CCR for CC chemokines, CXCR for CXC chemokines an so fourth [22]. Indeed, redundancy 
in chemokine-ligand/chemokine-receptor interactions seems evident (Figure 2). However, 
these interaction charts are mainly based on results obtained in vitro and it is probable that 
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this apparent redundancy is artificial in nature and absent in vivo. Further knowledge 
regarding subtle regulatory mechanisms, such as contribution of chemokine receptors to 
lymphocyte extravasation and serial usage of different chemokine receptors, might help to 
break this seeming redundancy [13]. Although the main task of cytokines is to orchestrate 
leukocyte recruitment, they also exhibit other cytokine-like activities including regulation of 
angiogenesis [23], fibrosis [24] and apoptosis [25].  
 
Figure 2) Human chemokines, encoded by 43 genes, are classified into four families on the 
basis of structural differences. Chemokines can also be classified as pro-inflammatory (red), 
homeostatic (green) and those with mixed function (yellow). Chemokines bind to a subfamily 
of seven-transmembrane G-protein-coupled receptors, which at present include 18 receptors 
that are classified as CCR, CXCR, CX3CR and XCR on the basis of the class of chemokines 
they are able to bind. Their main expression pattern on leukocytes is listed in the right 
column. To show the connection between receptors and cell types a notation inspired by 
electronic circuit representation has been used. To connect receptors to target cells, follow a 
horizontal line and turn on a vertical one at each node; the rhombs (diamond shapes) 
aggregate vertical lines to the cell type. Figure fully borrowed from A. Mantovani et al. [13]. 
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Growth factors 
The term growth factor refers to proteins capable of stimulating cellular proliferation and 
cellular differentiation. Growth factors play a crucial role in a variety of cellular processes. 
For example, the vascular endothelial growth factor (VEGF) family consists of important 
signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic 
circulatory system) and angiogenesis (the growth of blood vessels from pre-existing 
vasculature) [26]. The term growth factor became interchangeable with the term cytokine, 
when it became apparent that lymphocytes were also using some signaling proteins originally 
identified in hematopoietic context [27]. However, the term growth factor implies a positive 
effect on cell division, whereas cytokine is a neutral term with respect to whether a molecule 
does or does not affect cell proliferation. 
Peptide hormones 
It is known that hormones can suppress or activate the immune system depending on the 
specific context [28]. In opposition to cytokines, which can be produced by a wide variety of 
cells, specialized cells, mainly residing within endocrine glands, such as the pancreas, form 
peptide hormones. However, also non-endocrine glands, such as adipose tissue, produce 
peptide hormones e.g. leptin [29]. In addition, it should be taken into account that 
mononuclear cells express receptors specific for neurotransmitters, another class of signaling 
molecules mainly produced by highly differentiated cells [30]. Unfortunately however, the 
crosstalk between the nervous and the immune system is poorly explored [31]. 
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On autoimmunity, immune tolerance and autoimmune diseases 
Autoimmunity refers to the capacity of somatically generated antigen receptors to recognize 
self-molecules. Through the process of recognition, self-molecules can become self-antigens 
or autoantigens [6, 7]. The classical view on the relationship between autoimmunity and 
autoimmune diseases is based on the assumption that autoimmunity cannot be physiological. 
Hence, a healthy immune system must be free from autoimmunity. Several clues are used by 
the immune system to distinguish self-ligands from non-self ligands, e.g. the encounter with 
the ligand while the lymphocyte is still immature and the exposure to high and constant 
concentration of the ligand in absence of co-stimulatory signals. The latter is usually 
dependent on the activation state of the innate immune system [7]. This view defines 
autoimmunity in general as a random accident, which has no purpose and is always forbidden 
[32]. Autoimmune diseases, in such a case, must either be caused by a failure in eliminating 
an autoimmune clone during its development, through the mutation of a mature clone, which 
accidentally resulted in the recognition of a self-molecule, or be initiated by mechanisms of 
molecular mimicry. The absence of an autoimmune disease would therefore be marked by the 
absence of autoreactive clones. Such clones, because they evidently arise through random 
generation of TCRs and BCRs must all be deleted. Following this train of thought, the only 
specific cure for an autoimmune disease is the elimination of autoreactive cells. F.M. Burnet 
and P.B. Medawar were awarded the 1960 Nobel Prize for the discovery of acquired immune 
tolerance also known as the clonal deletion theory [32].  
Despite the plausibility of the clonal deletion theory, it became evident that the concept could 
neither always fit the state of a healthy immune system nor explain certain basic phenomena 
from autoimmune diseases [6, 7]. Nevertheless, autoimmune diseases are the result of a loss 
in immunological tolerance, which is the ability to appropriately respond to self-molecules. 
The exact conception of the nature, origin and maintenance of the immunological tolerance is 
still elusive, but several theories have been proposed, complementing, and in certain aspects 
opposing the clonal deletion theory e.g. the clonal anergy theory [33, 34] and the idiotype-
anti-idiotype network theory [35]. Furthermore, hypotheses involving specific regulatory cell 
populations with the function to limit or downregulate pathogenic autoimmune reactions are 
under intense investigation [19, 36].  
Today, one may imagine the existence of two types of autoimmunity: On one hand natural or 
physiological autoimmunity and on the other hand pathological autoimmunity. The latter is 
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manifested as a disease caused by an immune reaction specifically directed against self-
antigens (autoimmune disease) [6, 37].  
Indeed, autoimmunity might be an intrinsic and essential part of the healthy immune system, 
vital to its development and function especially in the context of immunological tolerance. 
According to I.R. Cohen, physiological autoimmunity should be viewed as an organized 
entity of a few key self-molecules [38]. The entity was termed the “immunological 
homunculus” analogous to the concept of the neurological homunculus, which refers to a 
functional map of the body in the brain [6]. Applying the same concept, the immunological 
self-determinants forming the immunological homunculus would define the borders between 
the self and the non-self. Indeed, the immune system consists of a relatively high number of 
autoreactive T- and B-cells, which recognize a relatively small number of immune-, 
maintenance- and tissue molecules [39-41]. Accepting the principle of natural autoimmunity 
has far reaching consequences as it implies that our immune system possesses a dynamic 
picture of the self. Such a picture would be drawn by the components involved in the 
maintenance of physiological autoimmunity [38]. Autoimmunity would no longer only be an 
aberration, but specific self-molecules would have the central role in shaping the immune 
response in accordance with the system’s state. Thereby they are subjected to strict anti-
autoimmune regulation [42]. These self-determinants and their corresponding counterparts of 
the immune system would be crucial in preventing the conversion of autoimmunity into an 
autoimmune disease. Hence, autoimmune diseases would arise from a divergence between the 
actual tissue state and the immune system’s perception of the situation and be marked by 
insufficient anti-autoimmune regulation against key self-molecules. Treatment of autoimmune 
diseases should be designed to reinitiate healthy immune regulation, which in its turn would 
be followed by reinstatement of physiological autoimmunity [36]. Administration of self-
antigens taking into account dose, dose schedule, anatomical site and context can prevent or 
in some cases induce remission of autoimmune diseases in murine models [43-45]. Similar 
results can be achieved by antigen unspecific stimulation of regulatory mechanisms [46]. 
The number of medically defined autoimmune diseases is relatively small and the different 
diseases mostly present distinct clinical and immunological signatures, which involve specific 
sets of self-antigens. Nevertheless, the lack of an knowledge regarding causative mechanisms 
renders disease classification difficult [47]. Nonetheless, autoimmune diseases can be 
clustered into organ-specific autoimmune diseases e.g. insulin-dependent diabetes mellitus 
(IDDM), primarily affecting the insulin producing pancreatic islets, and into systemic 
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autoimmune diseases, which can affect many and very diverse tissues of the body. The latter 
category includes diseases such as scleroderma, rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) and Sjögren’s syndrome (SS). It is important to notice that in several 
medical conditions described above, not only inappropriate destruction, but also inappropriate 
healing may contribute significantly to the pathogenesis [16]. Both processes are closely 
connected to the immune system and the state of inflammation. It is evident that the most 
difficult task of the immune system is the establishment of effective host-defense against 
foreign pathogens as well as against cancer cells while sparing healthy tissue and insuring 
proper instauration of tissue homeostasis. 
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Heat-shock protein 60kDa and the regulation of inflammation 
Classical anti-inflammatory drugs which can be grouped into corticosteroids, cytotoxic drugs 
and fungal and bacterial derivatives are very broad in their actions [7] and opportunistic 
infection are common complications of immunosuppressive therapies. Recent treatment 
strategies specifically induce the blockade of several pro-inflammatory cytokine pathways, 
such as TNF-α [48] and IL-1 [49]. However, none of these strategies reverse the pro-
inflammatory process and still harbor the risk of opportunistic infections [50, 51]. Indeed, it is 
obvious that patients suffering from autoimmune diseases would greatly benefit from 
restoration of immunological tolerance. Among other agents, heat-shock protein 60kDa 
(Hsp60) [52] and anti-CD3 [19] are representatives of a new category of biological agents 
endowed with the unique capacity to promote immunological tolerance in absence of long-
termed and generalized immunosuppression. 
Heat-shock proteins (HSPs) are ubiquitously expressed molecular chaperones, which have 
crucial housekeeping functions in both prokaryotic and eukaryotic cells by ensuring proper 
folding of proteins [53]. The expression of HSPs is markedly upregulated under conditions of 
cellular stress, such as an infection, inflammation and exposure of the cell to toxins. HSPs 
were also proven to be highly immunogenic [53]. Analyses of the T-cell response against 
Mycobacterium tuberculosis demonstrated that 10-20% of the response was directed against 
M. tuberculosis Hsp60 [54]. Exceptionally conserved throughout evolution, molecular 
mimicry between HSPs from microbial and HSPs form mammalian origin was suspected to 
underlie several autoimmune and inflammatory conditions such as RA [55] and 
atherosclerosis [56]. Hsp60 was also identified to be the crucial component in Bacille 
Calmette-Guérin mediated inhibition of IDDM in NOD mice [57]. Subsequently, a peptide 
vaccine (DiaPep277, aa437-460), based on eukaryotic Hsp60, has been developed for the 
treatment of IDDM and is currently tested in phase II clinical trials [58]. In contrast, HSPs 
remain a poorly investigated field in SS [59]. However, molecular mimicry does not seem to 
be the only origin of Hsp60 autoimmunity. Interestingly, despite multiple checkpoints, which 
could ensure central tolerance to self-Hsp60, healthy individuals maintain T- and B-cells 
recognizing exclusively self-Hsp60 [41]. In addition, abundant thymic overexpression of 
Hsp60 could not abolish T-cell responses to Hsp60 [60].  
It is most probable that T-cells recognizing self-Hsp60 receive yet undefined survival signals 
during negative selection in the thymus. As postulated by I.R. Cohen, Hsp60 belongs to a set 
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of conserved self-antigens at the core of physiological autoimmunity, which he termed the 
immunological homunculus [6]. After entering the periphery, the lack of clonal exclusion in 
the thymus must be compensated by mechanisms of peripheral tolerance. Several lines of 
evidence indicate that under certain conditions CD4+ T-cells specific for Hsp60 self-epitopes 
critically regulate inflammation [52].  
Therapeutic and preventive effects, irrespective of the specific autoimmune condition studied, 
have been attributed to the capacity of Hsp60 to trigger anti-inflammatory and regulatory 
mechanisms. Importantly, it seems that the protective effects of Hsp60 do not require an 
antigenic relationship between Hsp60 and the disease causing antigen [52]. Disease severities 
of RA and more recently of juvenile idiopathic arthritis have been related to the extent of 
Hsp60 induced propagation and activation of Tregs [61, 62]. Hsp60 and the Hsp60 derived 
peptide aa437-460, via TLR2 signaling, altered inflammatory chemotaxis and downregulated 
T-cell migration in vitro [63, 64]. Tregs, identified to be innately responsive to Hsp60, are 
supposedly rendered more effective in downregulating CD4 and CD8 effector responses after 
Hsp60 and aa437-460 engagement [20]. In addition, Hsp60 may regulate TH1/TH2 
transcription factors and cytokine expression [65].  
Research efforts also expanded the focus from Hsp60 specific T-cells to antigen presenting 
cells, including macrophages and DCs. Antigen presenting cells may thereby directly interact 
with endogenous Hsp60 through identified receptors such as CD14, CD40, CD36, CD91, 
lectin-type oxidized low-density lipoprotein (LDL) receptor, TLR2 and TLR4, and other yet 
unidentified cell specific surface receptors [66]. If proven correct, self-HSPs would represent 
an interface between the innate and the adaptive immune system. However, the proclaimed 
induction of pro-inflammatory cytokine secretion, mediated by self-HSPs, has been suspected 
to originate from LPS contamination of the HSP preparations [67]. Nevertheless, subsequent 
studies were able to identify specific effects of mammalian HSPs, which could not be 
assigned to microbial HSPs. These effects seemed to be regulatory and anti-inflammatory in 
nature [52]. In summary, compared to microbial Hsp60, its mammalian counterpart may, 
instead of promoting a pro-inflammatory response, pave the path for a regulatory response 
through the adaptive arm of the immune system. 
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Biomarker discovery 
A biomarker is a substance or measurement that is indicative for a certain state of a living 
organism [68, 69]. Identification of specific biomarkers of autoimmunity and tolerance 
represents a major goal of clinical immunology [70]. At first, biomarkers should provide the 
physician with information about the patient’s individual disease risk or benefit his diagnosis. 
Biomarkers may further predict the disease course or point the physician towards the use of a 
specific treatment. Repeated measuring of adequate biomarkers may further allow to follow-
up on treatments responses.  
A validated biomarker, possessing one or several properties described above, reduces the 
often not graspable complexity behind the process it indicates, to a rather simple 
measurement. For, example, a high concentration of LDL combines complexities related to 
factors such as genetic background, metabolism, inflammation and state of blood vessels 
walls, to an indicator of atherosclerosis [71]. Compared to defined infectious diseases, where 
the presence of a defined causative agent facilitates such enterprise, the diagnosis and 
classification of autoimmune diseases remains largely based on clinical examination 
combined with traditional laboratory tests [47].  
Due to accessibility and the lack of extraction procedures, biological fluids are the targets of 
choice for the detection of biomarkers [68, 69]. The rationale, however, is strongly dependent 
on the assumption that the tissue of interest is in close contact with the biological fluid. In 
such a case alterations in the tissue-state would be prone to be reflected in the spectrum and 
amount of proteins liberated into the biofluid [68]. The recent development of sophisticated, 
large-scale and high-throughput genomic and proteomic platforms created unprecedented 
possibilities to identify novel biomarker signatures for autoimmune diseases [5, 68, 69]. The 
ultimate goals of such studies are to improve diagnosis, to assess individual risk, to predict 
and characterize the response to treatment and the identification of possible targets for 
therapeutic treatment intervention. However, there is an obvious gap between theory and 
reality, which is clearly illustrated when comparing the enormous amount of data acquired 
through genomic and proteomic methods focusing on body fluids and the rare emergence of 
new, clinically applicable biomarkers [68]. Technologies applied to biomarker discovery are 
either, at least theoretically, unbiased platforms e.g. mass spectrometry or biased 
technologies, such as bead-based multiplex immunoassays, antigen array and antibody array 
platforms [70]. The inherent bias in the latter category is due to the use of existing capture 
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agents such as purified proteins, peptides or antibodies. The choice of technology needs to be 
dictated by the hypothesis that is being tested and the availability of specific reagents [70]. 
Which technology platform most accurately mirrors the true situation is often difficult to 
estimate, highlighting the importance of appropriate and uniform guidelines for quality 
assurance and quality control. One important task in the future consists in the creation of 
bioinformatics for the analysis of disparate data sets such as transcript profiles, protein 
profiles, and cell-surface phenotypes [70, 72]. 
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Sjögren’s syndrome 
Overview 
SS is a chronic autoimmune disease mainly affecting the exocrine glands. Nearly all patients 
complain of a persistent feeling of dry mouth (xerostomia) and dry eyes (keratoconjunctivitis 
sicca) [73, 74]. These symptoms can be confirmed by objective tests, which show significant 
functional impairment of the salivary and lacrimal glands. Histological evaluation of these 
glands show large and persistent infiltrates of mononuclear cells, so-called foci. These consist 
of mainly T-cells and fewer B-cells. Beside lymphoid infiltration, acinar epithelial cell 
atrophy and progressing fibrosis can be observed. 
Affecting approximately 0.3-0.6% of the total population, SS is considered a very common 
rheumatic disease. With a ratio of 9:1 SS exhibits one of the highest female to male ratios of 
all autoimmune diseases. SS may extend from an autoimmune exocrinopathy to the 
manifestation of diverse extraglandular symptoms, such as involvement of the 
musculoskeletal, pulmonary, gastrointestinal, hepatobiliary, hematologic, vascular, 
dermatologic, renal and nervous system. Furthermore, the risk of developing non-Hodgkin’s 
lymphoma is thought to be increased 16 fold compared to the general population [75].  
SS may occur alone, then defined as primary SS (pSS), or in association with another defined 
autoimmune disease, e.g. SLE, RA or scleroderma, and is then defined as secondary SS (sSS). 
As true for most autoimmune diseases, the etiology of SS is at present unknown. However, 
environmental factors set against an appropriate genetic background may be capable of 
triggering SS.  
Traditionally, the loss of secretory capacity has been thought to be the direct consequence of 
glandular tissue being destroyed or replaced by infiltrating cells. The correctness of this 
assumption was, however, challenged by frequently observed discrepancies between the 
extent of destroyed glandular tissue and the remaining salivary secretion capacity. Processes 
disturbing the physiological cascade of saliva production and secretion have been proposed as 
a possible explanation for this phenomenon [76]. 
History, epidemiology, diagnosis and patient classification 
In 1933 Henrik Sjögren, a Swedish ophthalmologist, presented his doctoral dissertation 
entitled “Zur Kenntnis der Keratoconjunctivitis sicca” [77]. He reported detailed clinical and 
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histological findings in women presenting xerostomia and keratoconjunctivitis sicca. Together 
with RA, SS is one of the most frequent autoimmune diseases and occurs in large parts of the 
world. The disease can appear at any age with a significant peak incidence between 40-50 
years of age. 
As there is no single test for the diagnosis of SS, different classification criteria have been 
proposed. Depending on the applied classification criteria, the prevalence of SS reaches from 
0.5% of the adult female population, when applying the Californian Fox Criteria [78], to 1-3% 
of the total population, when using the European Community Criteria [79] or the American-
European Consensus Group criteria (AECG) [47]. However, most studies act on the 
assumption of a prevalence of 0.3-0.6% of the total population. All three methods of 
classification listed above are based on the following disease manifestations: 1) subjective 
feeling of dry mouth and dry eyes, 2) objective ocular and oral signs of dryness, 3) defined 
focal lymphoid infiltrates within the salivary glands and 4) the presence of specific 
autoantibodies. 
Clinical manifestations of Sjögren’s syndrome 
Beside general discomfort, dry mouth is accompanied by problems in swallowing, speaking 
and alterations in taste, and the lack of tears by photosensitivity and fluctuating vision [80]. 
Indeed, deficiencies in saliva quantity and quality have a negative impact on dental and oral 
health. Dental caries, mucositis, oral candidiasis and swelling of the salivary glands are the 
most frequent oral signs of SS and edentulous patients are common [81]. Increased levels of 
acidogenic and aciduric microorganisms were found in most patients with SS [82]. 
Consequently, prevention of caries and oral infections is strongly indicated and drugs with 
anti-cholinergic side effects, e.g. anti-depressants and anti-histamines, should be avoided. 
Beside sicca symptoms, pain and especially fatigue contribute to the significant decrease in 
quality of life and a worsened psychological status in SS patients compared to the general 
population [83].  
Treatment of patients with Sjögren’s syndrome 
Treatments applied today provide merely marginal symptomatic relief [84] and patients with 
SS have to face a life with the disease. Keeping the mouth moistened, using water followed 
by a saline mixture, is the simplest solution to treat xerostomia. Extensive use, however, may 
remove the small amounts of mucous saliva, resulting in the dilution of protective agents 
present in saliva e.g. mucins. Dry eyes can be treated with protective measures, ocular wetting 
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agents and occasionally with local application of cyclosporine [85] and IFN-α [86]. To 
stimulate salivary flow, oral administration of muscarinic receptor agonists (pilocarpine 
hydrochloride or cevimeline) [87] were shown to significantly improve local and systemic 
symptoms of SS.  
Drugs acting as muscarinic agonists have become accepted for the treatment of SS [88, 89]. 
However, the effectiveness of these depends upon intact receptor structures and parenchyma. 
Another potential treatment involves the administration of intravenous immunoglobulin 
(IVIG) [90]. Antiidiotypic antibodies, being part of IVIG, remove the inhibitory activity of 
anti-muscarinic M3 receptor (M3R), an antibody potentially involved in the pathogenesis of 
SS, in vitro [91].  
Hydroxychloroquine [92] and nandrolone [93] also improved systemic symptoms of SS, 
whereas the usage of cyclosporine was rather ineffective [85]. Depletion of mature B-cells 
using anti-CD20 antibodies, first tested in small patient groups, which developed lymphoma 
[94, 95] or manifested severe systemic symptoms [96], also ameliorated several symptoms in 
a more representative SS cohort [97]. The use of TNF-α antagonists for the treatment of SS 
was not sustained since promising results could not be confirmed [98, 99]. 
Unfortunately, all therapies applied today are inadequate to cure SS and regrettably, the 
number of clinical studies addressing SS is significantly lower than for most other, as 
common, autoimmune diseases. 
Etiology of Sjögren’s syndrome 
A possible scenario for the emergence of SS comprises a viral infection of the target organs 
[100-102]. Subsequently, the immune attack, initially serving the purpose of host-defense, 
may, through molecular mimicry, be converted into a pathological immune reaction, which 
directly targets self-molecules.  
Another concept follows the perception that autoimmune diseases arise from a divergence 
between the actual tissue state and the immune system’s perception of the situation [38]. 
Autoimmune diseases, in such a case, would be marked by insufficient anti-autoimmune 
regulation against key self-molecules.  
As for other autoimmune diseases, a genetic predisposition for SS seems to exist [103]. 
Analyses of HLA-DR and HLA-DQ gene segments in patients with SS, revealed an increased 
prevalence of haplotypes B, Drw52 and DR3 [104]. However, better correlations were found 
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between HLA-DR haplotypes and the presence of anti-Ro and anti-La than with disease 
severity or disease development [104]. Recently, a variant of the minor histocompatibility 
antigen HA-1 was associated with reduced risk of pSS [105]. In contrast, no association with 
polymorphisms in Fas and FasL [106], IL-10, TNF-α, IL-1 receptor antagonist (IL-1RA) 
[107], cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) [108], TNF-α R2 [109] and 
CCR7 [110] was observed.  
The infectious agents which have received most attention in the field of SS are Epstein-Barr 
virus [100], human T-cell leukemia virus-1 [101] and hepatitis C virus (HCV) [102]. 
Association of SS with all these candidates remained, however, rather weak. Sialoadenitis, 
now considered as extrahepatic manifestation of chronic HCV infection, received some 
attention in the newly proposed AECG, in which HCV infection is listed as an illegibility 
criterion in clinical studies investigating SS [47]. A more recent study identified a Coxsackie 
virus as a potential agent involved in the induction or maintenance of SS in a Greek 
population [111]. However, the results could not be validated in a French patient cohort [112]. 
Konttinen et al. speculated that due to their anatomical localization and their short excretory 
ducts, the small exocrine glands should be considered as a locus minoris resistentiae, where 
apoptotic acinar cells may be unconventionally displayed to the immune system [113]. 
Interestingly, autoantigens associated with SS (Ro52, Ro60 and La48) are nuclear proteins, 
which are redistributed and exposed on the cellular surface during apoptosis [114].  
Microarray-based investigations of the salivary gland tissue transcriptome in SS patients [115, 
116] and in congenic mouse models of SS [117, 118] showed an activated type I and type II 
IFN system. Such activation, potentially originating from a viral infection, may be 
perpetuated by RNA-containing immune complexes, in their turn activating plasmacytoid 
DCs to prolong IFN-α production at the tissue level [119]. The finding that U1 snRNA and 
hY1RNA have the capacity to induce IFN-α further argues for the existence of such a vicious 
circle [120]. 
Female predominance and the late onset of SS directed the attention towards sex hormones 
and their role in the etiology of SS. In general, androgenic hormones have been considered to 
protect from autoimmunity and it has been proposed that women with SS are androgen 
deficient [121]. Whereas neither estrogen receptor-α nor estrogen receptor-β deficient mice 
develop SS, another model of estrogen deficiency, the aromatase-knockout (ArKO) mouse 
develops a lymphoproliferative autoimmune disease resembling SS [122]. Microchimerism of 
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fetal cells may also play a role in generating an autoimmune potential in women who have 
been pregnant [123]. 
Experiments in non-obese diabetic (NOD) mice, which exhibited severe combined 
immunodeficiency (SCID) [124] and inhibitor of DNA binding 3 (Id3) deficient mice [125] 
indicate a possible relationship between defective organ development and the initiation of 
pathological immune reaction targeting the salivary glands. Interestingly, in the latter model, 
depletion of B-cells ameliorated the SS-related symptoms [126]. 
The salivary glands in Sjögren’s syndrome 
A scheme of possible events taking place in the salivary glands of SS patients is proposed in 
(Figure 3). Primarily for diagnostic purposes, a salivary gland biopsy is evaluated for the 
presence and frequency of focal cellular aggregates, defined as clusters of at least 50 
mononuclear cells [127].  
 
Figure 3) Proposed scheme of events related to the initiation and pathogenesis of SS. Figure 
adapted from N. Delaleu et al. [84]. 
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The infiltrates consist of T-cells, B-cells, DCs [119, 128] and macrophages [129]. Similar 
infiltrates were also found in other organs e.g. the lacrimal glands, the lungs, the thyroid gland 
or the liver obtained from patients with SS [74]. Analyses of gene expression profiles in 
salivary gland tissue from SS patients confirmed the presence of many aspects of chronic 
inflammation [115, 116]. Recent studies reported that approximately one in four SS patients 
exhibit ectopic germinal center (GC)-like structures in the minor salivary glands, a feature 
which might be associated with a more severe disease [130]. To what extent GC-like 
structures in the salivary glands overtake processes normally assigned to GC in the secondary 
lymphoid tissue remains to be proven. Furthermore, GC-like structures have been associated 
with the occurrence of lymphoproliferative disorders in SS [131]. However, similar signs of 
ectopic lymphoid tissue formation and lymphoid neogenesis also occur in synovia from RA 
patients [132], in thyroid glands of Hashimoto’s thyroiditis [133] and in gut mucosa in 
relation with infectious agents e.g. Helicobacter pylori [134]. 
Endothelial cells 
Lymphocyte migration is partly mediated by vascular cell adhesion molecule (VCAM)-1 and 
peripheral node addressin (PNAd) expressed on vascular endothelium (Figure 4). Inhibition of 
these two molecules or their ligands (α4-integrin, L-selectin and lymphocyte function-
associated antigen-1 [LFA-1]) showed a nearly complete block of lymphocyte migration into 
the lacrimal glands in NOD mice [135]. In contrast, mucosal addressin cell adhesion 
molecule-1, E-selectin or P-selectin did not seem to contribute to monocyte migration into 
lacrimal glands in NOD mice [135]. 
Epithelial cells 
The glandular epithelium in SS seems to be activated [136, 137], resulting in local production 
of several pro-inflammatory cytokines [138]. In addition, the presence of chemokines in 
epithelial cells has also been reported [139, 140]. Furthermore, epithelial cells of SS patients 
also express TLRs, which argue for a role of these cells in the disease [141, 142]. 
Nevertheless, whether epithelial cell activation is an initiating event or a secondary 
phenomenon requires further investigation. Epithelial cells also express Fas, FasL and BCL-2 
associated X protein (Bax), suggesting apoptosis as a mechanism of acinar cell destruction 
[143, 144]. However, despite aberrant expression of pro-apoptotic molecules, apoptosis might 
be a rare event in acinar and ductal cells of patients with SS [145]. Increased matrix 
metalloproteinase (MMP)-2, MMP-3 and MMP-9 activity was associated with changes in the 
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structural organization in the basal lamina and the apical surface of acini observed in patients 
with SS [146, 147]. 
 
Figure 4) An important feature in the regulation of lymphocyte recirculation is the ability of 
lymphocytes to recognize and bind to the surface of endothelial cells before migrating 
through the vessel into surrounding tissue. (1) Circulating lymphocytes enter high endothelial 
venules. (2) Initial transient tethering and rolling: most lymphocyte adhesion molecules such 
as L-selectin are found on the tips of the lymphocytes microvilli where they can easily contact 
the endothelium by binding glycosylation dependent cell adhesion molecule (GlyCAM)-1 or 
CD34. (3) Appropriate activating factors: chemokines such as CXCL13 encountered in the 
local environment render possible a first lymphocyte activation step which facilitates firm 
adhesion. Activated integrins LFA-1 and VLA-4 on lymphocytes interact with intercellular 
adhesion molecules (ICAMs) and VCAMs. (4) Lymphocyte diapedesis: migration through 
endothelium, from circulation to tissue, a process probably also directed by chemokines. (5) 
Migrated lymphocytes contribute to the local immune response. Figure adapted from N. 
Delaleu et al. [84]. 
T-cells 
Mononuclear cell infiltrates consist of up to 80% T-cells, representing a CD4+ to CD8+ T-cell 
ratio of more than two. Most CD4+ T-cells are of a primed memory phenotype (CD45R0+) 
and over 50% of all T-cells express CD40/CD40L [148]. In context with T-cell activation, 
HLA-DR and IL-2R were found on a large fraction of T-cells [136, 149]. Analyses of 
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complementarity-determining regions (CDR)3 showed some conserved amino acid motifs, 
suggesting a relatively limited number of recognized antigens [150]. High proportions of T-
cells express Fas and/or members of the B-cell lymphoma 2 (BCL-2) family [151]. However, 
it was also reported that neither Fas/FasL induced apoptosis nor apoptosis implicating the 
Bax/Bcl-2 pathway occur more often among infiltrating mononuclear cells in SS compared to 
control individuals [145, 152]. Analyses of circulating Treg population showed inconsistent 
results [153, 154], whereas in numbers they may be underrepresented in the salivary glands 
[154].  
Cytokines and chemokines in Sjögren’s syndrome 
As crucial modulators of the immune system, cytokines represent potential drug targets. The 
therapeutic impact of agents neutralizing the pro-inflammatory cytokine TNF-α in patients 
with RA is indeed remarkable [48] and proves the coherence of this rationale. Cytokine 
profiles have been studied in blood and salivary gland tissues from patients with SS [138, 155, 
156] and in mouse models for SS [157]. However, because cytokines are characterized by 
redundancy, pleiotropism, synergism, and antagonism, the interpretation of cytokine-related 
data is often difficult. Applying the by now expanded concept of TH1/TH2 cytokines and 
autoimmunity, it has been postulated that TH2 cytokines may be predominant in an early 
phase of SS, while TH1 cytokines would be associated with a later stage of the disease [158]. 
In opposition stands the proposed principle, that the decrease in salivary flow, which is 
thought to follow the emergence of glandular inflammation [159], might be associated with 
TH2 cytokines [160-162]. In NOD mice the development of sialoadenitis and hyposalivation 
seems to critically depend on IFN-γ [163], whereas transition between the pre-clinical and the 
overt disease state, manifested by the onset of hyposalivation, has been associated with IL-4 
[160, 161] and the STAT6 pathway [162]. The revision of the TH1/TH2 paradigm was caused 
by the emergence of a T-helper cell subset termed TH17, producing IL-17 (IL-17A), IL-17F 
and IL-22 [15]. A major role of IL-17 has been described in various models of immune 
mediated tissue injury and autoimmune diseases, e.g. RA [15]. Interestingly, a recent study, 
also reported an activated TH17/IL-23 system in patients with SS [164].  
Chemokines are small secreted proteins implicated in leukocyte chemoattraction, 
angiogenesis, fibrosis and malignancy [13]. Despite their uncontested potential as candidates 
for therapeutic intervention therapies, few studies examined chemokines in SS [155]. The 
chemokines CXCL13, CXCL12 and CCL21 were expressed in acinar and ductal epithelium 
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cells from patients with pSS and sSS [165]. However, in NOD mice injection of anti-CXCL12 
antibodies was effective in preventing diabetes and insulitis, but did not affect the SS-like 
disease [166].  
Generation of the patient’s individual cytokine and chemokine profile, using a bead-based 
multiplex immunoassay, revealed biomarker signatures in serum potentially indicating the 
presence or absence of GC-like structures in the salivary glands [155]. Among 25 biomarkers, 
discriminant function analysis identified BAFF, CCL11 and IFN-γ levels to discriminate best 
between patients with and without GC-like structure formation [155]. 
B-cells 
Phenotypical analyses of B-cells from patients with SS revealed decreased numbers of 
circulating CD27+ memory B-cells [167, 168], which selectively overexpressed CXCR3 and 
CXCR4 [169]. In contrast, the fraction of CD27+ memory B-cells within the glands was 
enlarged [168]. Extensive analyses of mature B-cell subsets (Bm1-Bm5) in blood further 
showed altered proportions of most mature B-cell subsets in pSS compared to healthy donors 
and patients with RA [170].  
The percentage of B-cells expressing mutated V(H) genes was significantly higher in B-cells 
isolated from parotid glands compared to B-cells in circulation [171]. Furthermore, V(L) gene 
analysis of B-cells isolated from the glands revealed biased usage of V(L) chain genes [172]. 
However, if these alterations result from disturbed B-cell maturation and abnormal selection 
processes or if the biased repertoire reflects a normal antigen-driven local immune response is 
unclear. Polyclonal B-cell activation may develop into an oligo- or monoclonal B-cell 
expansion during disease progression. Such expansion may provide a basis for the initiation 
of a malignant lymphoproliferative disease [173, 174]. 
B-cell activating factor  
BAFF, a relatively new member of the TNF superfamily, is regulated by IFN-γ and has 
received considerable attention in the field of SS after it was reported that mice transgenic for 
BAFF develop a secondary pathology reminiscent of SS [175]. Closer investigation of the 
BAFF system in the field of B-cell biology demonstrated the need of an obligate survival 
signal for both, maturing and fully differentiated B-cells [11]. Taken together, BAFF is 
suggested to lower the threshold required for B-cell survival what may allow autoreactive B-
cells to escape from apoptosis and to exhibit their autoimmune potential [11]. 
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In patients with SS, elevated levels of circulating BAFF were reported to correlate with 
increased autoantibody titers [176]. Increased BAFF expression was furthermore observed 
within salivary glands of patients with SS [177], together with a significantly lower rate of 
apoptosis among the BAFF expressing cells [178]. BAFF levels were also increased after the 
discontinuation of an anti-CD20 therapy what may promote the reemergence of autoreactive 
B-cells [179]. Counteracting the BAFF triggered repopulation of the periphery with 
pathogenic autoreactive B-cells may therefore further improve the success of B-cell depletion 
in SS [97]. 
Autoantibodies in Sjögren’s syndrome 
Patients with pSS often present increased levels of polyclonal IgG in the serum [74]. 
Augmented production of IgM and IgG compared to IgA was further detected within labial 
salivary glands from patients with SS [180]. Autoantibodies specific for Ro (SSA) and La 
(SSB) are associated with SS and of major importance in SS diagnosis and patient 
classification [47]. 60-80% of the patients present anti-Ro and 40-60% anti-La antibodies in 
the serum [74]. Studies have shown that reciprocal spreading to the Ro52, Ro60 and La 
polypeptides occurs following immunization with a single component [181, 182]. 
Intermolecular epitope spreading suggests little tolerance to Ro and La in the B-cell and the 
T-cell compartment [183, 184]. Even though the role of Ro and La in the pathogenesis of SS 
is still elusive, recent research efforts reanimated the discussion, if Ro52 might directly 
contribute to the induction of autoimmune T- and B-cells in SS [185]. In addition, 
immunization of Balb/c mice with specific Ro peptides recapitulated the serological pattern, 
pathological findings and salivary gland dysfunction of SS [186]. 
Rheumatoid factor (RF) is produced in approximately 60% of the patients [187], whereas 
anti-cyclic citrullinated peptide (CCP) antibodies are rarely found in patients with SS [188]. 
Other antibodies found in patients with SS are anti-α-fodrin [189, 190] and anti-phospholipid 
antibodies [191]. The latter antibody could not be associated with any of the typical clinical 
manifestations of SS [192] and anti-α-fodrin autoantibodies are a controversial issue, since 
the original findings were difficult to verify [193]. 
Despite sizable research especially on anti-Ro and anti-La, the role of autoantibodies in the 
pathogenesis of SS remains ambiguous. Additional research efforts are necessary to reveal, if 
autoantibodies may be more than just bystanders of a T-cell mediated autoimmune disease as 
it has been proposed initially. Research initiatives, which identified autoantibodies inhibiting 
42 
neuronal innervation of acinar cells in the process of saliva secretion, are considered a major 
advance and these studies assigned for the first time a specific pathogenic role to an 
autoantibody in SS [194, 195]. 
Mechanisms mediating salivary gland dysfunction 
The original model to explain impaired salivary secretion in SS suggested the loss of 
glandular epithelial cells, secondary to apoptosis and T-cell mediated cell death, as the main 
reason for hyposalivation [196]. However, the frequently observed lack of correlation 
between the amount of destroyed glandular tissue and the often disproportional decrease in 
salivary flow [197] is difficult to fit into this model. In addition, glandular tissue from SS 
patients retains a certain functionality when tested in vitro [198]. Subsequent studies 
investigated immune-mediated mechanisms, which could cause chronic inhibition of the 
secretory function prior to glandular destruction and atrophy (Figure 5). A model of SS 
pathogenesis comprising mechanisms of glandular dysfunction [76] is further supported by 
the observation that certain mouse strains retain full secretory function despite severe 
glandular inflammation [199].  
Acinar cell innervation and humoral immunity 
The secretion of water and electrolytes from acinar cells is directly induced by acetylcholine 
and substance P released by the innervating parasympathic nerve ends [200]. In the salivary 
glands M1R and M3R are the predominant acetylcholine receptor subtypes, whereas M3 is 
predominant in the lacrimal glands [201]. Moreover, experiments in knockout mice revealed 
the crucial role of the M3R in the process of saliva secretion [202]. 
NOD Igµnull mice lack functional B-cells and despite the focal appearance of T-cells in the 
salivary glands NOD Igµnull mice failed to develop hyposalivation [194]. Reversible induction 
of hyposalivation through serum transfer from old NOD mice and IgG fractions from SS 
patients in these mice [194] further supports the notion of a contribution of serum components 
to the pathogenesis of SS. Functional analyses demonstrated that IgG fractions from patients 
with pSS reduced the carbachol-evoked increase in Ca2+ in murine and human acinar cells 
[195]. Due to the laborious method, however, both tests described above may be inadequate to 
screen large patient cohorts. The use of M3R tranfectants in combination with flow cytometry 
[203] or the application of newly developed enzyme-linked immunosorbant assays (ELISAs) 
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[204], may represent an alternative to further investigate the role and diagnostic value of anti-
M3R antibodies in SS.  
 
Figure 5) Proposed mechanisms mediating glandular destruction and dysfunction in SS. (1) 
Altered apoptosis of glandular epithelial cells. (2) Antibodies targeting the M3R may directly 
be related to impairment of the salivary glands by inhibiting neuronal innervation of acinar 
cells. (3) Aquaporins (AQPs) are suggested to play a major role in water transport through 
cell membranes. AQP-1 expression was decreased in myoepithelial cell from patients with SS. 
(4) AQP-5 expression may be decreased in acinar cells from patients with SS. Figure adapted 
from N. Delaleu et al. [73]. 
Acetylcholine ligation to M3R has also been shown to protect cells from apoptosis in vitro 
[205]. Inhibition of anti-apoptotic effects mediated trough M3R signaling could potentially 
link functional quiescence with cellular destruction. In addition, it should be taken into 
account that mononuclear cells express muscarinic receptors, secrete acetylcholine and 
encode the synthesizing choline acetyltransferase and the degrading acetylcholine esterase 
[30].  
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Aquaporins 
Aquaporins (AQP) are transmembrane proteins, which form channels in the cell membrane 
and increase the water permeability of the lipid bi-layer by up to 100 fold [206]. Different 
isoforms exist and show specific cellular and subcellular distributions in salivary and lacrimal 
glands. AQP-5 is located in the apical membrane of acinar cells, AQP-3 is present within the 
basal membrane of acinar cells and AQP-1 is expressed on myoepithelial cells [207]. 
Monoclonal anti-M3R antibodies had the potential to prevent translocation of AQPs to the 
plasma membrane [208]. Since then, AQPs have been suspected to contribute to the loss of 
exocrine gland secretory function in SS. Mice deficient of AQP-5 exhibit an approximate 
decrease of 65% in salivary secretion capacity compared to wild-type mice [209]. However, 
analysis of AQP-5 distribution within the glandular tissue from SS patients showed 
controversial results [210, 211]. AQP-1 expression was decreased by 38% in salivary glands 
of patients with SS suggesting a possible insufficient AQP-1 dependent water flow across 
myoepithelial cells [212].  
Inflammatory mediators 
Cytokines such as IL-1β may disturb the process of saliva secretion by inhibiting the release 
of acetylcholine from cholinergic nerves [213, 214]. Evidence against interferences of such 
kind was, however, presented recently. The study showed no relation between concanavalin 
A-induced cytokine production and acetylcholine evoked Ca2+ mobilization [215].  
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Model organisms in Sjögren’s syndrome research 
A model organism is a species, which can be studied extensively to explain a biological 
phenomenon observed in another species. One thereby anticipates that discoveries made in the 
model organism can provide information about the organism of primary interest. Model 
organisms are chosen based for several traits such as genetic background, possibilities for 
experimental and genetic manipulation, size, generation time, accessibility and potential 
economical benefit. In immunological research, the classical model vertebrate, the mouse, is 
the most widely studied.  
The use of murine models in SS research allows to follow the progression of the disease in a 
controlled environment [199]. Genetically altered strains enable the close investigation of a 
specific protein, a certain cell type or a certain mechanism and how it may contribute to the 
aspects of the disease. Furthermore, studying potential treatments regarding their capacity to 
modulate SS may lead to better therapies in the future.  
Ideally, a model for SS should present a high disease penetrance rate and exhibit clinical, 
histopathological and immunological features of the human disease. 
Spontaneous models of Sjögren’s syndrome 
Mouse strains which naturally develop an autoimmune condition resembling SS were first 
described in 1968 [216]. Subsequently, numerous studies confirmed the existence of focal 
inflammation within the lacrimal and salivary glands from strains traditionally studied for 
SLE. These include NZB, NZB/NZW [216] and the MRL mouse with its substrains [217]. 
Later a SS-like disease has also been described in NOD mice [218], NFS/sld mice [219] and 
IQI/Jic mice [220]. The fact that these models develop SS spontaneously mimics the complex 
situation found in patients. However, such complexity is challenging and may often hinder the 
formulation of clear-cut answers regarding the contribution of a single process. Nevertheless, 
the overall functioning principles cannot easily be predicted by studying the properties of its 
isolated components because they may strongly rely on each other or arise from the 
interaction of numerous constituents. 
NZB and NZB/NZW F1 mice 
In NZB/NZW F1 mice, glandular inflammation is more pronounced in females compared to 
males, whereas this phenomenon is generally less apparent in NZB mice [216, 221]. These 
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reports established the NZB/NZW F1 mouse as a model of progressive focal sialoadenitis 
[222, 223], in which, however, glandular function and the presence of SS related 
autoantibodies have not yet been explored.  
MRL/+ and MRL/lpr mice 
In 1982 MRL mice were first reported to present periductal lymphoid infiltrates in the 
salivary glands [224]. Subsequently, a system to quantify the inflammation in the salivary 
glands was introduced [225]. Like in humans, aberrant antigen presentation by glandular 
ductal epithelium in close proximity to lymphoid infiltrates is thought to perpetuate activation 
of CD4+ T-cells. MRL/+ and MRL/lpr mice differ with respect to a mutation involving the 
Fas gene [226]. However, negative selection in thymus does not seem to be impaired [227] 
and despite a defective genetic background, MRL/lpr mice express a detectable amount of 
apoptosis-related Fas protein on lymphoid cells [228]. Nevertheless, defective apoptosis 
related to the /lpr mutation [228] resulted in increased susceptibility and severity of the 
disease, most likely through acceleration of the disease course.  
Immunohistochemical analyses suggested local activation of T-cells [225, 229] and their 
importance was further confirmed in T-cell transfer experiments [230]. Inflammatory lesions 
in autoimmune MRL/lpr mice are sites of local IFN-γ production [229] and B-cells produced 
IgA and IgM RF in salivary glands [231].  
A differentiated, age-related pattern of cytokines has been suggested to influence the 
development and progression of the autoimmune sialoadenitis in MRL/lpr mice. IL-1β and 
TNF gene transcripts were detected in the salivary glands before the onset of sialoadenitis, 
whereas IL-6 mRNA expression was detected at the time of onset [232]. Furthermore, 
perpetuation of autoimmune sialoadenitis in MRL/lpr mice was described in conjunction with 
low expression of TGF-β and IL-10 [233]. 
Nevertheless, despite female predominance and the rare occurrence of anti-Ro, the clinical 
hallmark of SS, hyposalivation, is absent in this model. 
NFS/sld mice 
The NFS/sld mouse provides a model for pSS, in which aberrant immune responses against α-
fodrin are facilitated [219]. A defect in salivary gland development leads to the cleavage of 
the structural protein fodrin by caspase. Subsequent to neonatal thymectomy, 3d-Tx NFS/sld 
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mice develop T-cell dominated infiltrates in the salivary and lacrimal glands. Sera from 
patients with SS were suggested to contain antibodies specific for fodrin 125kDa [189], 
however, the specificity of these autoantibodies for SS was not as high as originally thought 
[193]. In addition, secondary to the SS-like disease, 3d-Tx NFS/sld mice developed severe 
autoimmune lesions involving arthritis and interstitial pneumonia, as they aged [234]. 
IQI/Jic mice 
Moreover, IQI/Jic mice have been suggested as an animal model for SS [220]. Focal 
infiltration of lymphocytes with parenchymal destruction was noted in the lacrimal and 
salivary glands. Sialoadenitis progressed over time and seemed more prominent in females 
than in males. IQI/Jic mice also developed inflammatory lesions in multiple organs, such as 
the lungs, pancreas and kidney [235]. Kallikrein-13 (Klk-13) has recently been suggested to 
play a role as an autoantigen in the disease development in IQI/Jic mice [236]. 
Non-obese diabetic mice  
The NOD strain descends from a cataract-prone strain of outbred Jcl:ICR mice and is 
considered the best characterized model for SS and IDDM. Although some genetic loci 
related to diabetes (idd-loci) may contribute to the inflammatory changes in the exocrine 
glands, it seems that diabetes and SS develop independently from each other [237]. Diabetes 
in NOD mice is restricted to the expression of MHC I-Ag7, whereas NOD.B10.H2b mice, 
which are resistant against diabetes, still exhibit sialoadenitis and hyposalivation [238]. 
Nevertheless, these mice still presented perivascular inflammatory infiltrates and in some 
cases insulitis [239]. In addition, the extent and cellular composition of the glandular 
inflammation still remains to be explored.  
NOD mice in which the MHC H2g7 haplotype was exchanged for an H2q or H2p haplotype 
were also investigated [240]. In summary, the exchange of the H2 haplotype did not affect the 
frequency of sialoadenitis, although disease severity varied among the strains. In contrast, the 
development of insulitis was almost completely inhibited [240]. Interestingly, introduction of 
the H2q haplotype directed the autoimmune response towards production of lupus-types of 
autoantibodies and a higher incidence of kidney involvement. The latter phenomenon was 
also reported in relation with immunomodulatory treatments, capable of preventing diabetes 
in NOD mice [241]. 
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Nonetheless, the parental NOD strain remains the best characterized model for SS and 
represents a complex model involving genetics, sensitivity to exogenous factors and defects in 
central and peripheral tolerance [242]. The extensive general and diabetes related knowledge 
about the immune system of the NOD mouse might benefit SS-related research in the future. 
Intrinsic alteration in immune tolerance may further contribute to the reported susceptibility 
of the strain to develop autoimmune thyroiditis [243], SLE [241], myasthenia gravis [244] and 
autoimmune encephalomyelitis [242] as a result of specific manipulations. 
Focal lymphoid infiltration in the submandibular salivary glands can be observed from 
approximately 8 weeks of age onwards and they are similar in structure and cellular 
composition as the infiltrates in humans [199]. In NOD mice, alike in humans, chronological 
order of glandular inflammation, glandular dysfunction and glandular destruction, and the 
relation between histopathological manifestations and hyposalivation, still remain matters of 
speculation.  
In diabetes, several lines of evidence indicate that progression from early insulitis to overt 
diabetes is promoted by the loss of immunoregulatory cells, such as Tregs and invariant NK T-
cells within the islets [43]. Unfortunately, little is known about the role of such cells in the 
progression of SS. However, NOD mice deficient for E2F transcription factor 1 (E2f1), a 
regulator of T-cell proliferation, differentiation, and apoptosis, have a profound decrease in 
CD4+CD25+ Tregs and seem highly predisposed to IDDM and SS [245].  
Another possible link between SS and IDDM in NOD mice may involve common 
autoantigens. Disruption of the islet cell autoantigen 69kDa (ICA69) gene in NOD mice, a 
self-antigen associated with diabetes, which is expressed in the pancreas, but also in the 
exocrine glands, greatly reduced SS-related histopathology and glandular hypofunction [246]. 
T- and B-cell autoreactivity to ICA69 was detected in patients with pSS. In addition, 
immunotherapy, using a high-affinity peptide targeting ICA69-specific T-cells, reduced overt 
SS in wild-type NOD mice. However, a study based on a larger cohort of patients failed to 
confirm a role or true frequency of ICA69 autoimmunity in human SS [247]. 
In contrast to diabetes, experiments in NOD Igµnull mice revealed no crucial role for B-cells in 
the initiation phase of SS. Instead, the lack of functional B-cells circumvents the onset of 
hyposalivation in these mice [194]. Similar to SS in humans, AQP-5 may contribute to the 
reduced saliva secretion observed in NOD mice [248]. 
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Protection from IDDM in NOD mice has been associated with a shift from a TH1 to a TH2 
cytokine expression profile in β-cell specific autoreactive T-cells, which were observed as a 
result of appropriate treatment or genetic modification [43]. Subsequent studies indicated, 
however, that compartmentalization into disease promoting TH1 and protective TH2 cytokines 
may represent an oversimplification, which cannot always be applied to the pathogenesis of 
IDDM [249].  
Cytokines in the exocrine glands in NOD mice have been analyzed [250, 251] and local 
expression of IL-10 and IL-12 mRNA during the disease was reported. In addition, the 
presence of IL-1β, IL-2, IFN-γ and TNF-α was reported and IL-10 mRNA expression was 
associated with detectable expression of IL-2 and IFN-γ [250, 251]. The roles of TH1 and TH2 
cytokines in the pathogenesis of SS were assessed in NOD IL-4-/-[161], NOD.B10-H2b IL4-/- 
[160], NOD.B10-H2(b).C STAT6-/- [162], NOD IFN-γ-/- and NOD IFN-γ R-/- [163] mice. IL-
4-/- alike STAT6-/- deficient NOD mice retained salivary secretion rates similar to Balb/c mice 
and failed to produce M3R antibodies of the IgG1 isotype, despite the development of 
sialoadenitis [160, 162]. NOD IFN-γ-/- and NOD IFN-γ R-/- mice did not develop 
inflammation in the salivary glands and retained normal salivary secretion capacity, while the 
inflammation within the lacrimal glands persisted [163]. Interestingly, the strains defective for 
IFN-γ or IFN-γ R did no longer exhibit the alterations in glandular organogenesis, which were 
reported in the parental strain [163]. 
Congenic mice, in which NOD specific genetic loci were introduced on either a B6 [237] or a 
B10 [117] background, were generated to investigate the importance of specific gene regions 
in SS. Both strains were extensively analyzed regarding changes in gene expression [117, 
118]. Especially the C57BL/6.NOD-Aec1Aec2 strain may represent a valuable mouse model 
for SS [118, 164, 237, 252]. Nevertheless, the background strain C57BL/6 develops 
spontaneous organ-specific autoimmune lesions in the salivary glands and multiple other 
organs and produces a wide variety of autoantibodies [253]. These phenomena render it more 
difficult to draw conclusions regarding disease causing and disease promoting gene segments. 
Similar accounts for B10 mice, which, independently from genetic manipulation, 
spontaneously develop sialoadenitis [117]. Unfortunately this latter model has not yet been 
assessed for salivary gland hypofunction [117]. 
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Transgenic and knock-out models of Sjögren’s syndrome 
Cytokines 
By promoting growth and effectiveness of Tregs, IL-2 plays a crucial role in the maintenance 
of immunological self-tolerance. Inhibition of circulating IL-2 led to the aggravation of 
diverse autoimmune manifestations in NOD mice [243]. IL-2 and IL-2Rα deficient C57BL/6 
mice develop sialoadenitis, hyposalivation and histopathological manifestations related to 
other autoimmune diseases [254]. In conclusion, the impact of IL-2 indicates that in 
conditions with decreased regulatory cell populations the salivary glands are prone to exhibit 
autoimmune manifestations.  
C57BL/6 mice transgenic for IL-10 exhibit progressive histopathology and hyposalivation 
evocative of SS [255]. However, IL-10 gene transfer into NOD mice partially suppressed the 
appearance of SS-like features [256], what indicates a dual role of IL-10 in SS.  
Two research groups developed mice transgenic for BAFF, of which one has been assessed 
for SS pathogenesis. Both strains showed severe autoimmune manifestations resembling SLE 
including circulating immune complexes, anti-DNA antibodies, and immunoglobulin 
deposition in the kidneys [257, 258]. The strain investigated for SS presented lymphoid 
infiltrates in the salivary glands together with an approximate 70% decrease in salivary 
secretion capacity [175]. Major proportions of the infiltrating cells were classified as B-cells 
displaying a marginal zone (MZ)-like phenotype, which appeared to be crucial for the 
development of the SS-like disease in this strain [259]. Smaller populations were classified as 
B-1 cells [175]. Disruption of the TNF-α gene in BAFF transgenic mice revealed a crucial 
role of the anti-tumor activity of TNF-α in this model [260]. 
A resent study investigated the role of IL-14α, in the pathogenesis of SS [261]. IL-
14α overexpression in C57BL/6 mice was accompanied by increased numbers of B-1 cells, 
followed by sialoadenitis and the development of CD5+ B-cell lymphoma. Unfortunately, 
salivary gland function was not evaluated and SS related antibodies were not found. In 
addition to SS-like features, IL-14α transgenic mice exhibit immune-complex mediated 
nephritis [261].  
TGF-ß1 is a multifunctional molecule, which has regulatory effects on many developmental, 
physiological and immunological processes. Animals homozygous for the mutated TGF-ß1 
allele present a syndrome marked by mixed inflammatory cell responses and tissue necrosis 
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leading to organ failure and death [262]. The syndrome also includes inflammation of the 
exocrine glands, in about 50% of the animals. The inflammation could be prevented by 
systemic injections of synthetic fibronectin peptides and subsequent reversal of the acinar and 
ductal alterations suggest that salivary gland development is not impaired in the absence of 
TGF-β1 [263]. 
Id3-/- knock-out mice 
Id proteins are inhibitors of basic helix-loop-helix transcription factors and act as positive and 
negative regulators of proliferation and differentiation of immune and non-immune cells, both 
in embryonic and developed tissue [264]. The immune system of Id3-/- mice is characterized 
by alteration in humoral immune reactions, MZ B-cell development, B-cell precursor survival 
and both MHC I and MHC II restricted positive and negative selection [265]. Tissues such as 
salivary glands, which undergo epithelial-mesenchymal interactions, seem to have a tendency 
to express Id genes. Id3 is, furthermore, implicated in angiogenesis in normal and tumor tissue 
[264, 266]. In the Id3-/- model, T-cell dominated focal inflammation developed between 6 and 
12 months, together with production of anti-Ro and anti-La. These mice, however, showed 
severe exocrine gland dysfunction at 6 to 18 weeks already, long before the appearance of 
focal mononuclear cell infiltration in the exocrine glands [125]. Nevertheless, the notion that a 
single gene disruption triggers distinct pathological changes, almost exclusively limited to the 
salivary and lacrimal glands, encourages the investigation of possible interrelationships 
between organ development and the initiation of autoimmune diseases. Interestingly, 
depletion of B-cells ameliorated the disease symptoms of SS in these mice [126]. 
Aromatase-deficient mice 
Estrogen is a crucial factor regulating gender differences of the immune system. The reported 
effects of estrogen are, however, contradictory [267, 268]. Whereas neither estrogen receptor-
α nor estrogen receptor-β deficient mice develop SS, another model for estrogen deficiency, 
ArKO mice develop a lymphoproliferative autoimmune disease resembling SS in parallel with 
B-cell infiltration in the kidneys and enlargement of the spleen [122].  
R1Δ/R2n mice 
Mice with a T-cell specific loss of phosphoinositide 3-kinase class IA (PI3K Ia) develop 
inflammation resembling SS in addition to lymphoid infiltration in the lungs, liver and 
intestines [269]. Whereas secretory function was not addressed in detail, the authors reported 
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decreased Tregs in the periphery and increased anti-Ro and anti-La antibodies as a result of the 
genetic modification.  
Models of experimentally induced Sjögren’s syndrome 
Carbonic anhydrase 
Patients with autoimmune diseases including patients with SS may produce autoantibodies 
against carbonic anhydrase II (CAII) [270]. Indeed, experimental sialoadenitis was induced 
through CAII immunization in PL/J mice [271]. PL/J mice with different H-2 haplotypes, 
bearing H-2s and H-2u, were also susceptible to CAII-induced sialoadenitis [271]. However, 
further studies are required to be able to estimate the resemblance of this model with SS in 
humans. 
Ro peptide 
Repeated intraperitoneal injection of Ro peptides emulsified in complete Freund’s adjuvant 
(CFA) and incomplete Freund’s adjuvant (IFA) recapitulated SS in Balb/c mice [186]. These 
mice showed decreased salivary gland function, SS-like histopathology and production of 
anti-Ro and anti-La at 38 weeks of age [186]. Oral feeding of Ro or Ro peptide could, in 
addition, partly prevent the induction of the SS-like disease through the immunization 
protocol described above [45]. These findings reanimate the discussion, whether 
autoreactivity towards Ro, due to molecular mimicry or aberrant expression, may play a role 
in the etiology of SS.  
Murine cytomegalovirus  
To elaborate a possible viral etiology of SS, four different murine strains (B6, Fas-deficient 
B6-lpr/lpr, B6-tnfr1-/-, and B6-tnfr1-/--lpr/lpr) were infected intraperitoneally with murine 
cytomegalovirus (MCMV) [272]. Beside sialoadenitis, B6-lpr/lpr mice, developed anti-Ro 
and anti-La antibodies. Apoptotic cells were detected during the acute, but not during the 
chronic phase of the inflammation. Both Fas- and TNF RI-mediated apoptosis seemed to 
contribute to the clearance of MCMV infected cells in salivary glands. Indeed, such defects 
may lead to a post-infectious, chronic inflammation resembling the histopathology of SS. In a 
subsequent study, FasL mutant B6-gld/gld mice were infected with MCMV to evaluate the 
therapeutic value of FasL expression by local gene transfer using recombinant adenoviral 
vectors [273]. Despite high levels of FasL expression after injection of recombinant vectors, 
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less than 5% of ductal and acinar cells were TdT-mediated dUTP-biotin nick end labeling 
(TUNEL) positive. Nevertheless, a significant reduction in the number of inflammatory foci 
and tissue destruction in salivary glands was observed as a result of local FasL gene transfer 
[273]. 
 
None of this makes sense; Illustration by Sam Brown (www.explodingdog.com) 
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Aim of the studies 
Paper I 
The aim of the study was to characterize the chronology of the disease course of SS in NOD 
mice and to study possible interrelationships between salivary gland inflammation and 
hyposalivation. In addition, ten cytokines were analyzed in saliva and serum to identify 
alterations in cytokine patters associated with a specific disease stage.  
Paper II 
The aim of the study was to expand the knowledge regarding 87 analytes in serum and 75 
proteins in saliva. Based on direct comparison with Balb/c mice we intended to identify 
differentially expressed proteins and investigate their potential to discriminate between the 
disease model and the control strain. This pool of data should also allow computation of a 
correlation network, representing associations of biomarkers with relevant clinical features of 
SS in non-diabetic NOD mice, both systemically and locally.  
Paper III 
The aim of the study was to investigate a potential immunomodulatory effect of Hsp60 and 
aa437-460 on spontaneous experimental SS. Comprehensive biomarker profiles were 
generated to identify biomarker signatures related to the treatment, treatment efficacy and 
exocrine function. 
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Material and Methods 
Mice (Paper I-III) 
Animals studied in Paper I, female NOD and Balb/c mice, were purchased from Taconic 
(Bomholtgård, Denmark). The animals were maintained under standard animal-housing 
conditions at the Section for Physiology, Department of Biomedicine, University of Bergen, 
Norway. In Paper II & III, female NOD/LtJ (stock #001976) and Balb/cJ (stock #000651) 
mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed in sterilized individually 
ventilated cages at the same animal facility alluded to above. Mice were fed with autoclaved 
RM1 pellets, (Special Diet Service, Witham, UK). All handling procedures were carried out 
in a laminar flow hood. All studies have been approved by the Committee for research on 
animals/Forsøksdyrutvalget, Project #79-04/BBB and Project #12-05/BBB, respectively.  
Immunization (Paper II & III) 
In Paper II, at 7 weeks of age, 22 NOD mice and 20 Balb/c mice were injected 
subcutaneously with 25 µl IFA emulsified in PBS. In Paper III, additional 32 female NOD 
mice (16/group) were immunized subcutaneously with 50 µl of one of the following agents 
emulsified 1:1 in IFA: 50 µg low-endotoxin (< 0.05 endotoxin units/µg) human recombinant 
Hsp60 (#ESP-540G; Stressgen, Ann Arbor, MI, USA) [274] or 100 µg of aa437-460 
(VLGGGVALLRVIPALDSLTPANED) synthesized using 9H-fluoren-9-ylmethoxycarbonyl 
based solid-phase peptide synthesis (Fmoc SPPS) at Invitrogen (Carlsbad, CA, USA). The 
peptide was purified using high-performance liquid chromatography (HPLC) to ensure > 95% 
purity.  
Assessment of diabetes (Paper I-III) 
In Paper I, serum glucose levels were measured the day of euthanasia using Reflotron Plus 
Glucose test kit (Roche Diagnostics, Laval, Quebec, Canada). In Paper II & III, from 10 
weeks onwards NOD mice were screened weekly for diabetes. Two repetitive measurements 
of glucosuria (Figure 6) (> 50 mg/dl; Keto-Diabur-Test strips, Roche, Mannheim; Germany) 
were considered to represent onset of diabetes and confirmed by measurement of blood 
glucose levels (> 300 mg/dl; Ascensia microfill, Bayer healthcare, Mishawaka, IN, USA). At 
week 20 and 21, all mice were screened for hyperglycemia. 
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Figure 6) Urine collection for the screening for glucosuria in mice. The procedure is carried 
out in a laminar flow hood. 
Measuring salivary secretion capacity (Paper I-III) 
Mice were fasted for a minimum of 2 hours, but given water ad libitum and anesthetized with 
an intramuscular injection of ketamine/medetomidine (0.01 ml/g bodyweight). In Paper I, 
after stimulation of secretion by pilocarpine (#P6503; Sigma, St. Louis, MO, USA) in saline 
(0.5 µg/g bodyweight) administered via the femoral artery, saliva was collected with capillary 
tubes for 10 minutes, and the volume was determined. The samples were stored at -80°C until 
analyzed. In Paper II & III, salivary secretion was induced by intraperitoneal injection of 0.5 
µg pilocarpine per gram bodyweight (#P6503; Sigma) and collected during 10 minutes 
(Figure 7). Pre-weighted tubes were weighted again after collection to determine the amount 
of saliva (1 µg = 1 µl). Protease inhibitor cocktail (#P8340; Sigma) was added at a 
concentration of 1:500 and samples were kept at -80°C until analysis. 
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Figure 7) Saliva collection and measurement of the salivary flow rate in anesthetized mice 
subsequent to the intraperitoneal injection of pilocarpine.  
Blood sampling and organ collection (Paper I-III) 
Blood was collected from the saphenous vein from non-anesthetized mice and by heart 
puncture on the day of euthanasia. The blood was allowed to clot and centrifuged at 800 g to 
obtain serum. In Paper I, submandibular and sublingual salivary glands were surgically 
removed, snap-frozen in isopentane by liquid nitrogen and stored at -80°C. In Paper II & III, 
organs were fixed in 4% formalin before embedding in paraffin, sectioning and staining with 
haematoxylin and eosin (H&E). Sections obtained from the kidneys were also stained using 
the periodic acid-Schiff (PAS) staining technique. 
Histopathology and quantification of inflammation (Paper I-III) 
Histopathological evaluations in Paper I are based on frozen tissue and in Paper II & III on 
paraffin embedded tissue. H&E staining was carried out to determine the degree of 
inflammation. In Paper I, submandibular and sublingual salivary glands were snap-frozen in 
isopentane by liquid nitrogen, and stored at -80°C. Five µm thick sections were cut using a 
cryostat (Leica Instruments, Nussloch, Germany) and placed onto SuperFrost Plus glass slides 
(Menzel, Braunschweig, Germany). Salivary gland sections were evaluated and analyzed 
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using a Leica DMLB light microscope connected to a ColorView III-camera and AnalySIS 
software (Soft Imaging System GmbH, Munster, Germany), to determine the focus score (FS; 
number of foci of 50 or more mononuclear cells/mm2 of glandular tissue), and the ratio index 
(RI; area of inflammation/area of glandular tissue). In Paper II & III, FS and RI were 
determined as followed: three independent H&E stained sections of each salivary gland were 
qualitatively evaluated; the section displaying the highest degree of inflammation was 
recorded as a multiple image composite, displaying the whole surface of the gland (80x 
magnification); total glandular area and the individual size of each focus were 
morphometrically analyzed (Lucia, Laboratory Imaging, Hostivař, Praha). To determine the 
insulitis score (IS), at least five H&E stained tissue sections of the pancreas were analyzed in 
a blindly fashion. On average, 32 islets (Paper I) and 46 islets (Paper II) per mouse were 
evaluated in a blinded manner and scored as described by E.H. Leiter [275]. Sections of the 
kidneys, thyroid gland, thymus, heart, lungs, liver, stomach, small and large intestine, 
appendix and the skin were also stained with H&E. 
Immunohistochemistry (Paper I) 
Immunostaining was performed by the AvidinBiotinComplex using the following antibodies: 
for T-cells (CD4), rat IgG2b,k, clone GK1.5 (R&D Systems, Abingdon, UK); for B-cells 
(B220), rat IgG2b, clone RA3-6B2 (R&D Systems); for proliferating cells (Ki-67) rat IgG2a, 
clone TEC-3; and for follicular DCs (FDC), rat IgG2c, clone FDC-M1 (BD Biosciences, San 
Jose, CA, USA). Briefly, following fixation in cold acetone, endogenous peroxidase 
(Blocking kit) and biotin were blocked (Avidin D and Biotin blocking solution, Vector 
Laboratories, Burlingame, CA, USA). Non-specific binding was inhibited by normal rabbit 
serum. Diaminobenzidine was used as chromogen. Unless otherwise specified, all reagents 
were purchased from DAKO (Glostrup, Denmark). 
Multiple analyte profiles (Paper I-III) 
In Paper I, serum and saliva samples obtained from the mice were analyzed using a bead-
based multiplex sandwich immunofluorescence assay (#LMC0001; BioSource, Nivelles, 
Belgium), as recommended by the manufacturer, measured on a Luminex 100 system 
(Luminex Corporation, Austin, TX) and analyzed using StarStation software (Applied 
Cytometry Systems, Dinnington, Sheffield, UK). 
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In Paper II & III, a similar bead-based multiplex assay (Figure 8) was applied to generate 
multi-analyte profiles (MAPs) from serum and saliva from the 12 non-diabetic NOD and 12 
Balb/c mice comprising 82 analytes for serum and 75 for saliva. MAPs were generated for 
every individual non-diabetic NOD mouse assessed for SS (n = 36) and 12 Balb/c, which 
were randomly selected from the original cohort of 20 PBS/IFA injected Balb/c mice. Results 
were obtained using a multiplex sandwich immunofluorescence assay based on color-coded 
and antibody coated beads, carried out at Rules Based Medicine Inc. (Austin, TX, USA). 
Using an automated system for liquid handling, each sample was introduced into the capture 
microsphere multiplex of the MAP. After incubation, multiplexed cocktails of biotinylated, 
reporter antibodies were added, developed with a streptavidin-phycoerythrin solution and 
analyzed using a Luminex 100 instrument (Luminex Corporation). For each multiplex, 8-
point calibrators and 3-level controls were included. Antibodies used in the MAP to recognize 
and quantify the specific autoantibodies were directed against all Ig isotypes. 
 
Figure 8) Bead-based multiplex immunoassay A) The combination of two unique dye 
intensities allows the labeling of up to 100 sets of color-coded microspheres each possessing 
a unique spectral signature. Each color-class of beads is subsequently labeled with capture 
antibodies. Subsequent to a classical sandwich immuno-assay procedure, a Luminex analyzer 
is used to measure the quantity of each analyte included in the assay. Fluidics based on the 
principle of flow cytometry cause the stream of suspended microspheres to line up in a single 
file prior to passing the detection chamber. One laser classifies the microparticle and 
determines the analyte that is being detected and the second laser determines the magnitude 
of the streptavidin-phycoerythrin-derived signal, which is in direct proportion to the amount 
of bound analyte. Figure adapted from www.rndsystems.com. 
Quantification of anti-M3R antibodies (Paper II & III) 
Levels of anti-M3R autoantibodies were measured as described previously [160]. In brief, 
aliquots of 2 x 105 Chinese hamster ovary cells, transfected with pcDNA5/FRT/V5-His 
MsM3R-Flp-In cells, were incubated for 1.5 hours at 4°C with 10 µl of serum before 
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incubation with one of the following FITC-conjugated goat anti-mouse detection antibodies 
purchased from Southern Biotech (Birmingham, AL, USA) diluted 1:50: isotype control, goat 
IgG (#0110-02); IgG H+L (#1031-02); IgG1 F(ab’)2, (#1072-02); IgG2b F(ab’)2 (#1092-02); 
IgG2c F(ab’)2 (#1079-02) and IgG3 F(ab’)2, (#1102-02). The cells were analyzed using a 
FACSCalibur flow cytometer using Cell Quest software (BD Biosciences) and FlowJo (Tree 
star Inc., Ashland, OR, USA). 
Statistical analyses 
Paper I: Data were analyzed using one-way analysis of variance followed by the Bonferroni 
posttest for selected groups (modified unpaired Student’s 2-tailed t-test for multiple group 
comparisons). To normalize skewed distributions and improve the homogeneity of variance, 
cytokine data were log-transformed prior to all statistical analyses. To determine the linear 
relationship between 2 variables, values were compared using Pearson’s correlation test (2-
tailed). Correlation analyses were restricted to NOD mice and data sets in which a scientific 
reason for a causal connection was given. P values less than 0.05 were considered significant. 
Statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad Software 
Inc., San Diego, CA, USA).  
Paper II: Means were compared using independent Student’s t-test (2-tailed). Bivariate linear 
associations, used to generate the correlation matrices, were computed using 2-tailed Pearson 
correlation (r). Strain-membership prediction was assessed by discriminant analyses (DA) and 
subsequent cross-validated (leave-one-out) group prediction. The quality of the DA function 
is expressed by its canonical correlation (R*).  
Principal component analyses (PCA) were computed from MAPs obtained from NOD mice 
with the purpose to uncover the latent structure within protein families. Protein family 
membership was defined based on the Protein ANalysis THrough Evolutionary Relationships 
(PANTHER) classification system (http://www.pantherdb.org). PCA seeks a linear 
combination of variables so that the maximum variance is extracted from the variables. It then 
removes this variance and seeks a second linear combination and so forth. Loadings above 0.6 
were considered as defining parts of the component. For proper model specification, variables 
being either differently expressed between the two strains (P < 0.05) and/or significantly 
correlated (r > 0.6; P < 0.05) with one of the disease parameters were included. As a rotation 
method Varimax was chosen. The number of components was determined by the Kaiser 
criterion (Eigenvalue > 1.0). An explanatory criterion (> 80%) was applied, in addition, for 
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growth factors and cytokines in serum. Variables being the defining parts of a component 
were also combined for DA and entered simultaneously. In serum no data was missing and in 
saliva missing values were excluded pair-wise from all analyses except PCA and DA. All 
analyses were computed using SPSS 13 (SPSS Inc., Chicago, IL, USA). 
Paper III: Means were compared to the specific reference group using 1-way Anova and 
Dunnett’s post-test (2-tail), accounting for multiple group comparison. Due to comparison of 
all pairs, salivary flow means were analyzed using Bonferroni’s posttest. Prior to original and 
cross-validated (leave-one-out) group prediction the discriminant potential of the respective 
variables was computed using DA. Variables were entered simultaneously or in a forward 
stepwise manner, using Wiki’s lamda as the inclusion/exclusion criteria. Relative risk and 
incidences were compared using Fisher’s exact test (2-tail). P values less than 0.05 were 
considered significant. Statistical analyses were computed in SPSS 13 (SPSS Inc.) and Prism 
4.0 (GraphPad Software Inc.). 
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Summary of the results 
Paper I 
NOD mice retained stable salivary secretion during the period of time in which the major 
histopathological changes in the salivary glands took place. The significant decrease in 
salivary secretion capacity occurring between 17 weeks and 24 weeks of age, was, in contrast, 
not accompanied by significant changes in the degree of salivary gland inflammation. T- and 
B-cells marked the chronic inflammatory cell infiltrates within the salivary glands and in one 
third of the mice early signs of ectopic lymphoid organization were observed. Significant 
quantitative changes in IL-2, IL-5, and GM-CSF in serum and in IL-4 and TNF-α in saliva 
occurred within the time period characterized by the onset of hyposalivation. Correlation 
analyses revealed a negative association between salivary secretion and the levels of IL-4, 
IFN-γ and TNF-α in saliva obtained from NOD mice, while correlation between salivary flow 
rates and parameters of glandular inflammation were consistently weak. 
Paper II 
A total of 162 analytes, for which often only scant or no information in SS has been 
published, was analyzed in serum and saliva from NOD and Balb/c mice. The application of 
multiplex technology significantly diminished the sample volume required and enabled the 
investigation of the analytes’ connectivity through correlation networks. At 21 weeks of age 
all NOD mice presented glandular inflammation and impaired salivary secretion. The latter, 
when applied as a discriminant function, classified 100% of the mice according to their strain 
membership, confirming the onset of overt SS in all NOD mice. In addition, subsets of NOD 
mice presented histopathological changes in the kidneys and the lungs reminiscent of SS-
related extraglandular disease manifestations.  
Thirty-eight biomarkers in serum and 34 in saliva obtained from NOD mice were significantly 
different from Balb/c mice, which served as reference strain. Eighteen biomarkers in serum 
and 3 chemokines measured in saliva had the capacity to predict strain membership with 80-
100% accuracy. The extraction of principal components reduced the size of the correlation 
matrix considerably, from 9’604 to 1’994 coefficients. Correlation networks revealed a 
complete lack of original variables or components correlating with salivary flow and either FS 
or RI. This lack was also obvious when analyzing inter-component correlations. In contrast, 
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there were some components associated with either salivary flow or glandular inflammation 
having positive or negative interrelationships with components related to autoantibody levels. 
Among components associated with salivary flow, an antagonistic interplay between cytokine 
Sa-C-3 (associated with decreased salivary flow) and all three components extracted from 
serum (positively associated with salivary flow) became apparent. Components associated 
with FS and/or RI correlated strongly with each other, indicating a process in which cytokine 
Sa-C-2 and CXCL Sa-C-2 opposed acute-phase reactant Sa-C-1 and secreted IgA. In addition, 
cytokine Se-C-2 and coagulation factor Sa-C-2 played a dual role by combining the positively 
associated IL-1α and von Willebrand factor (vWF) with the negatively associated CD40L and 
fibrinogen, respectively.  
Paper III 
Immunizing NOD mice with Hsp60 and aa437-460 at 7 weeks of age significantly reduced 
SS-related histopathology compared to PBS/IFA injected NOD controls. At 21 weeks of age, 
salivary secretion in PBS/IFA injected NOD controls was decreased by 42% compared to 
Balb/c and DA confirmed the onset of hyposalivation in all PBS/IFA injected NOD controls. 
Mean salivary flow was higher in Hsp60 immunized mice and similar in the aa437-460 
injected group. Nevertheless, we observed an obvious dichotomy regarding salivary secretion 
capacity in both treated groups. Evidentially, they could be separated by choosing the highest 
salivary flow rate measured in PBS/IFA injected NOD controls as a threshold. Notably, 
salivary flow rates of mice immunized with Hsp60 or aa437-460 with salivary flow rates 
above the threshold did no longer present impaired salivary secretion compared to Balb/c 
mice. 
Importantly, except salivary secretion capacity, treated mice with retained salivary flow (n = 6 
Hsp60 and n = 4 aa437-460 treated) and treated mice with decreased salivary flow (n = 6 
Hsp60 and n = 8 aa437-460 treated) were very similar with respect to FS, RI and IS. In 
addition, we did not identify significant alterations in the frequency of extraglandular disease 
manifestations in response to the two treatments investigated. Both treatments induced similar 
changes in biomarker profiles. Notably, circulating inducible protein-10 (IP-10) and eotaxin 
decreased significantly as a consequence of the treatment. In contrast, anti-M3R IgG1, IL-10 
and leptin discriminated most accurately between the different treatment groups and, in 
addition, the PBS/IFN injected NOD controls (hitrate: 86.1% original and cross-validated). 
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Successful prevention of hyposalivation (treated mice with retained salivary flow) was 
accompanied by quantitative alterations in 36 biomarkers when compared to treated mice with 
decreased salivary flow. Nineteen inflammatory mediators, measured in the treated mice with 
retained salivary flow, thereby declined to levels comparable to Balb/c. Low salivary VEGF-
A was the best individual predictor of successful treatment, whereas high VEGF-A indicated 
the onset of hyposalivation despite Hsp60 or aa437-460 administration (hitrate 87.5% original 
and cross-validated). Expanding the model by including circulating apolipoprotein A1 (Apo 
A1) and secreted macrophage-colony stimulating factor (M-CSF) further improved prediction 
accuracy (hitrate: 91.7% original, 95.8% cross-validated). DA were also computed to identify 
sets of biomarkers with the highest potential to discriminate between normal and decreased 
salivary secretion capacity, irrespective treatment-group membership and strain. As most 
accurate single predictor granulocyte chemotactic protein-2 (GCP-2) in saliva was identified 
(hitrate 81.3%, original and cross-validated). A forward stepwise model combining salivary 
GCP-2 with circulating IL-1α and salivary myeloperoxidase (MPO), myoglobin and 
macrophage inflammatory protein (MIP)-3β resulted in 93.8% accurately classified cases, 
original and cross-validated. 
 
It might be useful one day; Illustration by Sam Brown (www.explodingdog.com) 
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General discussion 
The clinical symptoms of SS are thought to develop late in the disease course; thus, in most 
patients, SS is most likely diagnosed at an advanced stage [74]. Investigation of the SS 
disease course in humans is ethically difficult due to the lack of a non-invasive method for the 
quantification of salivary gland inflammation. Consistent with the results reported by other 
investigators [159], our results described in Paper I suggest that hyposalivation in NOD mice 
follow the emergence of focal lymphoid infiltration with a certain delay in time. 
Conventionally, the extent of impairment in exocrine function has been anticipated to be the 
direct outcome of the degree of glandular inflammation replacing and destroying parenchyma. 
Nevertheless, despite the soundness of the hypothesis, the frequently observed lack of 
correlation between the amount of destroyed glandular tissue and the disproportional decrease 
in salivary flow [197] was difficult to fit into this model. Consequently, processes disturbing 
the physiological cascade of saliva production and secretion have been proposed as a possible 
explanation for this phenomenon [76]. A model of SS pathogenesis acknowledging the 
existence of other pathogenic mechanisms than the sole destruction of glandular epithelium is 
further supported by several murine models of SS. MRL/lpr mice retain a stable salivary flow 
rate over time despite pronounced inflammation in the salivary glands and several other 
features of human SS [199]. The absence of overt SS in presence of sialoadenitis was, 
furthermore, described in NOD IL-4-/- [161], NOD.B10-H2b IL-4-/- [160] and NOD.B10-
H2(b).C STAT6-/- mice [162].  
One conclusion, common to all three studies combined in this thesis, is the apparent 
autonomy of the major SS-related disease manifestations. Results summarized in Paper I 
indicate that the development of hyposalivation is independent from a significant quantitative 
increase in glandular inflammation. In Paper II we describe the complete lack of original 
variables and extracted components correlating with salivary flow and either FS or RI. This 
lack was also evident when analyzing inter-component correlations. In Paper III, the effective 
protection from hyposalivation was associated almost exclusively with changes reflected by 
the MAP. At the same time we found neither protection nor manifestation of hyposalivation to 
be related to the quantitative degree of glandular inflammation. 
The findings in all three studies also support the notion that alterations within the salivary 
gland tissue are prone to be reflected in the spectrum and amount of proteins liberated into 
saliva. The identification of a set of biomarkers in human saliva, similar to the 3 chemokines 
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we described in Paper II, predicting the presence or absence of SS with high accuracy, or as 
described in Paper III, specific biomarker signatures capable of predicting treatment efficacy 
and capable to distinguish normal from impaired salivary secretion, would represent a major 
advance in the field. Due to the non-invasive collection method and the lack of extraction 
procedures, saliva based approaches are more applicable in clinical practice for prognostic, 
diagnostic and follow-up purposes than methods requiring salivary gland biopsies [47, 68, 
115]. Importantly, as described in Paper II, we could exclude a general concentration effect 
on biomarker quantities measured in saliva in relation with lower fluid secretion. This 
conclusion was based on the observation that in a non-inflammatory situation, represented by 
Balb/c mice, the average correlation coefficient of all analytes and analytes included in the 
modeling process did not show any sign of a negative association with salivary flow. Saliva, 
because it is directly collected from the site of inflammation, is most probably superior to 
measurement in serum in reflecting the immunological situation in the salivary glands [276]. 
The findings regarding extraglandular autoimmune manifestations in Paper II and Paper III 
also support this hypothesis.  
However, the presence of SS-unrelated histopathology and other subclinical autoimmune 
disease features remain a common problem of several murine models of SS [117, 199]. Such 
divergence from an “ideal” SS-specific situation may lead to false conclusions drawn from 
measurements in serum. Due to the complexity of this biofluid, one may also conclude that 
biomarker profiles solely relying on serum or plasma require considerable validation efforts to 
prove their specificity and sensitivity for a specific autoimmune disease such as SS [5, 68]. 
Nevertheless, analyzing the SS patient’s individual cytokine and chemokine profile in serum, 
using a bead-based multiplex immunoassay similar to the technology applied in Paper I-III, 
revealed that biomarker signatures in serum might indeed be able to indicate specific 
histopathological situations in the salivary gland. In this study, among 25 biomarkers, BAFF, 
CCL11 and IFN-γ levels discriminated best between patients with and without GC-like 
structures [155]. 
The formation of GC-like follicles in non-lymphoid organs has been suggested to indicate a 
more severe disease and through histopathological and immunohistochemical screening such 
structures were found in approximately every forth patient with SS [130]. Interestingly, in 
Paper I, the early signs of lymphoid organization in the salivary glands, defined by distinct 
areas of T-cells and B-cells, proliferating cells and FDCs, were associated with higher FS. 
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However, to what extent such structures overtake functional tasks normally assigned to 
secondary lymphoid organs remains to be proven.  
In Paper I we describe significant alterations in circulating IL-2, IL-5, and GM-CSF and 
secreted IL-4 and TNF-α occurring during the same period of time as the onset of 
hyposalivation. In contrast, no significant increase in glandular inflammation was observed 
within this specific period. By promoting growth and suppressor functions of Tregs, IL-2 is 
crucial in the maintenance of immunological self-tolerance. Neutralization of circulating IL-2 
led to aggravation of diverse autoimmune manifestations in NOD mice [243] and deletion of 
IL-2 and IL-2Rα in C57BL/6J mice caused the emergence of sialoadenitis, hyposalivation and 
SS-unrelated histopathological manifestations [254]. Even though the role of regulatory 
processes in the progression and perpetuation of SS is still elusive, the results published in 
Paper III indicate that lower salivary gland inflammation and especially the prevention of 
hyposalivation depends on the efficacy of Hsp60 and aa437-460 to strengthen regulatory 
processes.  
Although recent studies indicated that absence of IL-5 could induce a shift toward adaptive 
immune responses [277, 278], the decrease in circulating IL-5 reported in Paper I is difficult 
to interpret. Murine IL-5 acts on B-cells and contributes to the maintenance and 
differentiation of B-1a cells [279]. In atherosclerosis, natural autoantibodies secreted by B-1a 
cells recognizing LDL may exert a protective effect by preventing the implication of the 
adaptive immune system against this particular antigen [277, 280]. The significant negative 
correlation of secreted IL-5 with salivary flow reported in Paper II and of IL-4 with salivary 
secretion rates in Paper I further corroborates with the notion of TH2 cytokines and B-cells in 
the pathogenesis of SS [160, 161]. Most importantly, depletion of the patient’s B-cells, using 
anti-CD20 antibodies, was shown to ameliorate several symptoms of the disease [97]. TNF-α 
was upregulated in saliva during the overt stage (Paper I) and significantly decreased in NOD 
mice protected from hyposalivation (Paper III). The therapeutic impact of agents neutralizing 
TNF-α in patients with RA is indeed remarkable [48], however, the use of TNF-α antagonists 
in SS was discontinued since initial promising results could not be confirmed [99].  
In Paper II we present data on a considerable number of immunologically relevant proteins, 
for which often only little or no information in SS has been published. The possibility of 
multiplexing analytes significantly diminished the required sample volume and enabled 
investigation of the analytes’ connectivity through correlation networks [5]. Compared to a 
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component-focused experimental study design, such a study cannot be as conclusive in 
defining the role of a single protein. It rather represents a novel way of analyzing the 
implication of multiple molecules in a specific condition, also by utilizing the explanatory 
power of interrelationships, which define a specific system state [4]. Most system states in 
fact, arise from and strongly rely on the interactions of their numerous constituents [5]. 
Analyses of protein levels instead of mRNA expression data could rule out certain factors of 
uncertainty such as mRNA stability and correlation between mRNA levels and the 
corresponding protein levels. A recent study combining global mRNA expression analyses 
with 2-D gel electrophoresis coupled with mass spectrometry to analyze pooled saliva 
obtained from SS patients for the purpose of biomarker identification reported poor 
correlations between levels of transcripts and protein quantities [281]. The same study 
identified 42 proteins, significantly altered when comparing pooled saliva from SS patients 
with healthy controls [281]. Technologies and techniques in the field of quantitative mass 
spectrometry are evolving at a fast pace, now allowing first identifications of peptides, which 
could be of interest for preliminary validation steps [69]. Nonetheless, identification of 
immunological regulators, operating at nano- to picomolar concentrations using mass 
spectrometry, still represents a great challenge, as abundant proteins may mask the 
immunological modulators in the biofluid of interest [69]. The gold standard for such 
quantitative measurements is still the application of immunoassays as a result of their 
unmatched sensitivity provided by antibodies [68].  
Stable-isotope protein tagging or subtractive proteomics may, however, harbor the potential to 
significantly improve the number of immune system related proteins identified by mass 
spectrometry [69]. Nevertheless, the two approaches, antibody-based biomarker identification 
and mass spectrometry-based global proteome profiling, may well complement one another in 
delineating SS-specific disease signatures. Both technologies, however, need further 
technological advances to obtain a more complete coverage of crucial immune mediators and 
of the whole proteome, which consists of at least 100’000 constituents [69, 70]. Certain 
molecules of proven importance in the pathogenesis of SS, such as BAFF [175] and IFNs 
[119], were not part of our MAP. Storage of data in a structured format represents one option 
of including results from future studies in existing databases or correlation networks and 
would enable exciting new possibilities for automated and integrative biological research [5, 
70]. Standardizing reagents, assays, data storage, and normalization techniques are mandatory 
to achieve such possibilities in the future [70]. 
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In line with the results described in Paper I the data acquired in Paper II also argues against 
close interrelationships between the different SS-related disease manifestations. Only RI and 
anti-La/SSB correlated directly with each other and the segregation between proteins being 
either associated with hyposalivation or glandular inflammation was absolute. The 
chemokines, which were associated with higher salivary flow (MIP-1α and monocyte 
chemoattractant protein [MCP]-5) are considered TH1 related chemokines and are negatively 
regulated by STAT6 [282]. In contrast, the STAT6 dependent TH2 associated chemokines 
[282, 283] eotaxin and macrophage-derived chemokine (MDC) were associated with 
decreased salivary flow. Normalization of secreted MDC quantities to levels comparable with 
Balb/c mice was, in addition, observed in relation with the treatment-induced protection from 
hyposalivation described in Paper III. Both, eotaxin and MDC are produced by TH2-
promoting DC cell types upon engagement of CD40/CD40L [284] and these two molecules 
were associated with low salivary secretion capacity in the correlation network as well. 
Interestingly, CD40 and CD40L are expressed on salivary gland epithelial cells and 
infiltrating lymphocytes in biopsies obtained from SS patients [285].  
The observed correlation between CD40/CD40L and anti-M3R IgG3 levels may be associated 
with the primary role of CD40 and CD40L which is related to B-cell survival, B-cell 
proliferation, Ab production and Ab isotype switching [286]. In Paper II, all antibody 
isotypes against M3R were upregulated, with, perhaps most importantly, the positive 
associations between M3R IgG3 and secretory CD40, CD40L, IL-18, GCP-2 and MMP-9. 
IgG2 subclasses and IgG3 are generally considered to be significantly more potent in 
mediating pathogenic effects than IgG1 [287]. In contrast to other isotypes, the effect of IgG3 
is FcR independent and strictly related to complement activation, a component of the immune 
system recently related to SS pathology [252]. In addition, IgG3 can form complexes through 
self-association and generate cryoglobulins [287], a feature in SS [74]. However, previous 
studies concluded IgG1 to be the crucial isotype in anti-M3R antibody mediated 
hyposalivation due to its absence in STAT6 [162] and IL4 [160] deficient NOD related 
strains. In contrast, in Paper III, the induction of anti-M3R IgG1 was strongly related to 
immunization with Hsp60. However, in Paper III, the alterations in anti-M3R IgG1 levels 
were not related to the manifestation or protection from hyposalivation. 
Beside B-cell fate, CD40/CD40L ligation plays a central role in converting a tolerogenic 
antigen presentation into a pathogenic immune activation [288]. In conditions with chronic 
inflammation, CD40 and other inflammatory mediators can exert adverse effects on tissue 
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renewal and repair processes [289]. Indeed, we found specific growth factors e.g. epidermal 
growth factor (EGF) to be negatively correlated with CD40/CD40L and secreted 
autoantibodies.  
Furthermore, negatively correlated with CD40/CD40L was circulating IL-10, whose anti-
inflammatory properties may apply to our model, since in Paper II increased circulating IL-10 
did correlate with higher salivary flow and lower autoantibody concentrations in saliva. This 
observation is in line with the reported benefit of IL-10 gene transfer, which could suppress 
the emergence of certain SS-related manifestations in NOD mice [256]. However, IL-10 in 
saliva was associated with glandular inflammation, and the findings reported in Paper III did 
not mirror the conception of increased IL-10 secretion by Tregs in favor of immunosuppression 
[20]. These findings reinforce the results obtained in IL-10 transgenic mice, which developed 
progressive histopathology and hyposalivation, evocative of SS [255].  
With the exception of vWF, increased concentrations of proteins in saliva related to acute 
tissue injury were all associated with a lower degree of glandular inflammation. These events 
may be followed later on by inflammatory cell invasion into the glandular tissue and/or may 
mirror an imbalance between processes restoring homeostasis and factors promoting chronic 
inflammation. Higher levels of IL-1 family members correlated with both worsening of 
hyposalivation and increased glandular inflammation. GCP-2, inducible through IL-1β [290], 
was, alike IL-1β, associated with glandular inflammation. The levels of all these pro-
inflammatory proteins (IL-1α, IL-1β and GCP-2) declined in treated mice with retained 
salivary flow to levels comparable with Balb/c mice (Paper III). Leukemia inhibitory factor 
(LIF), also inducible through IL-1β [291], which was included in a component together with 
IL-1β and IL-10, has been shown to have parallels with IL-1, TNF-α and IL-6 related to the 
perpetuation of inflammation in RA [291]. Alike anti-TNF-α the inhibition of IL-1 pathway 
using recombinant IL-1RA has become an accepted treatment strategy in RA [292]. 
Unfortunately, clinical or experimental studies using IL-1RA in SS are still lacking. 
Among the biomarkers analyzed in saliva, GCP-2, IP-10 and regulation upon activation, 
normal T-cell expressed and secreted (RANTES), revealed the highest potential to distinguish 
between NOD and Balb/c. In addition, in Paper III, GCP-2, individually or combined with 4 
other analytes, accurately predict impaired salivary secretion capacity irrespective of 
treatment group-membership and strain. For clarification, GCP-2 is expressed at neutrophil 
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and macrophage dominated inflammatory sites, IP-10 is related to TH1 immune responses, 
and RANTES is involved in TH1 and TH2 immune responses [293].  
GCP-2 and IP-10 have opposite roles in angiogenesis [23], an aspect which, despite the 
recognized importance of neovascularization in promoting the influx of inflammatory cells 
[294], has not yet been addressed in SS. Proteins, such as GCP-2, VEGF, EGF, IL-1, VCAM-
1 and MMP-9, which were significantly increased in NOD mice compared to Balb/c (Paper 
II), are involved in angiogenesis [294]. In addition, also angiostatic molecules, such as IP-10, 
tissue inhibitor of metalloproteinase (TIMP)-1 and endostatin-1 [294] were also altered 
(Paper II). In Paper III, low VEGF-A, a key molecule mediating vascularization [26], was the 
primary predictor indicating the success or failure in preventing hyposalivation followed by 
low M-CSF, which is alike thrombopoietin (TPO) and oncostatin M (OSM), an inducer of 
VEGF-A [295]. Other molecules implicated in the process of neovascularization, which were 
decreased in saliva in concordance with prevention of hyposalivation in treated mice are, 
MMP-9, fibroblast growth factor (FGF)-9 [294], as well as all CXCR2 ligands measured 
(GCP-2, melanoma growth stimulatory-activity protein [GRO] and MIP-2) [13, 23]. The 
importance of neovascularization is greatly recognized in RA and has been explored as a 
target for therapeutic intervention [296]. Anti-VEGF therapies are also important in the 
treatment of certain cancers [297] and in age-related macular degeneration [298]. Anti-VEGF 
therapies can either involve monoclonal antibodies or orally available small molecules that 
inhibit the tyrosine kinases stimulated by VEGF [297]. Unfortunately, the issue of pathogenic 
neovascularization has not yet been addressed as a pathogenic mechanism in SS.  
The study presented in Paper III describes the first preventive antigen-specific intervention, 
successfully ameliorating spontaneous experimental SS. Despite the antigenic relationships 
between Hsp60 and antigens specifically related to SS are unknown, we provide further 
evidence that immune responses to Hsp60 are relevant in the control of pathogenic 
autoimmunity [52]. In line with the notion that Hsp60 and aa437-460 treatment can alter 
chemotaxis of T-cells in vitro [63, 64], decreased inflammation was associated with lower 
serum levels of chemoattractants for TH1 and TH2 cells [13] even 14 weeks after 
immunization. In addition, MCP-1 and MCP-3, to which monocytes and plasmacytoid DCs 
are most responsive [13], were also reduced in serum as a result of the treatment.  
Disease severity of RA and juvenile idiopathic arthritis have been related to the extent of 
Hsp60 induced propagation and activation of Tregs [61, 62]. Suggested key molecule involved 
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in this process is IL-10, which may be secreted upon Hsp60 signaling through TLR2 [20]. As 
described above, our findings, however, do not support a general anti-inflammatory role of 
IL-10 in SS. In contrast, increased salivary IL-2 and the observed modulation of leptin as an 
effect of Hsp60 and aa437-460 immunization support the notion of strengthened regulatory 
processes as a result of the treatments. Compared to IL-2, the adipokine leptin exerts a 
reciprocal effect on effector and Treg populations [29]. Besides Tregs, IL-17 cells raised 
considerable attention in the field of autoimmune diseases [12, 15] and a major role of IL-17 
has now been described in various models of immune mediated tissue injury related with host 
defense against microorganisms and organ-specific autoimmunity [15, 17]. Even though 
results in Paper II showed an increase of IL-17 in saliva from NOD mice, the treatment 
interventions described in Paper III were not accompanied by detectable alterations in IL-17, 
neither in saliva nor in serum. Recent results suggest that the TH17/IL-23 system is activated 
in SS patients and C57BL/6.NOD-Aec1Aec2 mice during the overt disease state. Functional 
associations between IL-17/IL-23 expression and specific clinical manifestations have, 
however, not yet been identified [164]. 
In Paper III, prevention of hyposalivation was achieved in a substantial number of mice at 
least for the duration of the experiment. Nevertheless, future studies need to elucidate if NOD 
mice can permanently be protected from developing hyposalivation and if such treatments 
may also be able to induce remission of SS. Refinement of treatment regimes, as it has been 
shown recently for diabetes using tandem repeated aa437-460 [299], may further increase the 
percentage of mice protected from hyposalivation. 
As in Paper II, the MAPs generated a comprehensive, but not all-embracing overview of the 
serum and salivary proteome in Paper III. The purpose of the analyses in this study was also 
to characterize the different disease phenotypes, which resulted from the treatments. The 
biomarker signature associated with successful prevention of hyposalivation in NOD mice 
was primarily coined by the decrease and normalization of multiple chemokine levels and 
proteins related to angiogenesis. Such modulation was potentially promoted by the 
simultaneous decrease in TNF-α and IL-7, both key antagonist of Treg induced 
immunoregulation [300]. Based on these variables, forward stepwise DA identified a model in 
which the combination of VEGF-A and M-CSF in saliva and Apo A1 levels in serum 
predicted the prevention of hyposalivation with 96% accuracy. 
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Downregulation of CD40, IL-10 and IL-11 [301] may further suggest TH2 associated 
responses to be modulated by the treatment. An effect of Hsp60 on B-cells through innate 
signaling pathways has been reported [302] and may also contribute to the modulation of 
autoimmune diseases with a confirmed or potential B-cell aspect. Nevertheless, in Paper III 
the levels of most autoantibodies remained unaffected. Another encouraging aspect of our 
study regards the capacity of GCP-2 which individually or combined with 4 other analytes, 
accurately predict impaired salivary flow. 
As alluded to already, we did not find significant associations between extraglandular disease 
manifestations and the biomarker profiles. Similarly, we did not identify significant 
alterations in extraglandular disease manifestations as a result of the two treatments 
investigated in Paper III. Nevertheless, it would be of interest to investigate in further detail 
the involvement of kidneys and lungs in both experimental and human SS [303-305]. The 
development of malignancy in one mouse remains difficult to interpret, as lymphoma develop 
rather frequently in old NOD mice [306]. There are conflicting data about whether there is an 
increased risk for lymphoma and solid malignancies with anti-TNF therapies for RA [292]. 
Nevertheless, anti-inflammatory treatment need to be critically reviewed regarding alterations 
induced, which could create immune privileges for tumor cells and microbial pathogens or 
host-defense related immunity. 
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Conclusions 
In analogy with the proposed specific aims, the following conclusions can be drawn: 
• The development of major focal inflammation in the salivary glands precedes the 
onset of hyposalivation with a considerable amount of time. 
• The onset of hyposalivation, which marks the onset of overt SS, can occur without a 
significant increase in salivary gland inflammation.  
• Changes in cytokine patterns in serum and saliva coincide with the transition from pre-
clinical to overt disease. 
• Processes related to the adaptive immune system seem to promote SS with a strong 
association between TH2 related proteins and the severity of hyposalivation. 
• The different disease manifestations of SS appear to be greatly autonomous from each 
other and they are associated with different immunological processes.  
• CD40, CD40L, IL-18, GCP-2 and anti-M3R IgG3 may represent a pivotal point, which 
intersects the different aspects of SS pathology.  
• Saliva represents an attractive biofluid for biomarker discovery in SS. 
• Immunization with Hsp60 led to inhibition of SS in NOD mice. 
• The Hsp60-derived peptide aa437-460, currently tested in phase II clinical trials for 
the treatment of IDDM, mimicked in general lines the beneficial effects of Hsp60. 
• Successful prevention of hyposalivation was related to a significant decrease in 
inflammatory mediators related to pathological neovascularization, inflammatory 
chemotaxis and cell activation. 
• Comprehensive analyses revealed specific biomarker signatures capable to predict the 
treatment received, treatment efficacy and impaired exocrine function. 
• MAP analyses provide a basis for the comparison and selection of potential drug 
targets and diagnostic markers and allow the characterization of treatment responses. 
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Future perspectives 
Although several hypotheses have been proposed over the last years, the etiology and several 
aspects regarding the pathogenesis of SS are still elusive. Unfortunately, all therapies applied 
today are inadequate to cure SS and regrettably, the number of clinical studies addressing SS 
is significantly lower compared to most other, as common, autoimmune diseases.  
In all three studies here presented, we found direct evidence that the immunological processes 
mediating the different SS-related disease manifestations are considerably independent from 
each other. Stratification of the disease course in patients with SS and the close investigation 
of the interrelationships between the different aspects of disease are important goals for the 
future. Given the limits of the current disease assessment, the development of non-invasive 
precise methods for the quantification of salivary gland inflammation would greatly facilitate 
such studies. In mice specific biomarker signatures had, on an individual scale, the potential 
to discriminate “sick” from “healthy”, successful prevention of hyposalivation from 
ineffective treatment of hyposalivation and intact salivary secretion capacity from impaired 
salivary secretion. It is unclear if these successful pilot studies conducted in an experimental 
model will translate into similar findings in an outbred human population. However, the 
methodology regarding MAP, data analyses and last but not least the results here presented 
will hopefully encourage researchers to conduct similar studies in samples collected from SS 
patients. 
Promoted by the revolution in information technology, advanced analytical platforms, such as 
multiplex immunoassays, mass spectrometry and mRNA microarrays, take an important place 
in today’s biomedical research. As reflected in this work and research efforts undertaken by 
other groups, such methodologies have to some extent been applied in SS. We believe that 
discovery-driven studies such as the one presented in Paper II, can widen the horizon and 
inspire new hypothesis-focused research. Bridging between these two approaches represents a 
great challenge for the years to come, which may, however, be rewarded with a more 
integrated perspective on immunology and autoimmune diseases.  
The enigma of the initiating event leading to the accumulations of mononuclear cells in the 
exocrine glands characteristic for SS has not yet been solved and the hunt for “the causing 
agent” over the last decades has yet left most questions unanswered. The paradigm of 
insufficient immune regulation against key self-molecules being at the origin of the 
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conversion from physiological autoimmunity into an autoimmune disease led to the 
emergence of new concepts for the treatment of autoimmune diseases. As indicated by our 
study investigating the immunomodulatory potential of Hsp60 and aa437-460, one may 
assume that these and similar biologics, which strengthen regulatory mechanisms, may lead to 
valuable alternatives for the treatment of SS. Such agents are often extensively studied and 
successfully applied in other autoimmune conditions than SS and appear to not induce long-
term immunosuppression. More frequent interdisciplinary collaborations may indeed take us 
all one crucial step towards a deeper understanding of SS and more appropriate measures for 
the treatment of SS. 
 
No one lets me know what I think; Illustration by Sam Brown (www.explodingdog.com) 
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